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ABSTRACT: 45 
Objective: Blood vessel epicardial substance (BVES) is a tight junction-associated 46 
protein that regulates epithelial-mesenchymal states and is underexpressed in epithelial 47 
malignancy. However, the functional impact of BVES loss on tumorigenesis is unknown. 48 
Here we define the in vivo role of BVES in colitis-associated cancer (CAC), its cellular 49 
function, and its relevance to inflammatory bowel disease (IBD) patients.  50 
Design: We determined BVES promoter methylation status using an Infinium 51 
HumanMethylation450 array screen of patients with ulcerative colitis with and without 52 
CAC. We also measured BVES mRNA levels in a tissue microarray consisting of normal 53 
colons and CAC samples. Bves-/- and wild-type mice (controls) were administered 54 
azoxymethane (AOM) and dextran sodium sulfate (DSS) to induce tumor formation. 55 
Lastly, we utilized a yeast two-hybrid screen to identify BVES interactors and performed 56 
mechanistic studies in multiple cell lines to define how BVES reduces c-Myc levels.  57 
Results: BVES mRNA was reduced in tumors from patients with CAC via promoter 58 
hypermethylation. Importantly, BVES promoter hypermethylation was concurrently 59 
present in distant non-malignant appearing mucosa. As seen in human patients, Bves was 60 
underexpressed in experimental inflammatory carcinogenesis, and Bves-/- mice had 61 
increased tumor multiplicity and degree of dysplasia after AOM/DSS administration. 62 
Molecular analysis of Bves-/- tumors revealed Wnt activation and increased c-Myc levels. 63 
Mechanistically, we identified a new signaling pathway whereby BVES interacts with 64 
PR61α, a PP2A regulatory subunit, to mediate c-Myc destruction.  65 
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Conclusions: Loss of BVES promotes inflammatory tumorigenesis through 66 
dysregulation of Wnt signaling and the oncogene c-Myc. BVES promoter methylation 67 
status may serve as a CAC biomarker.  68 
  69 
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SUMMARY BOX 70 
What is already known about this subject? 71 
 Patients with ulcerative colitis are at greater risk for developing colon cancer. 72 
 Blood vessel epicardial substance (BVES) is a tight junction protein that regulates 73 
epithelial-to-mesenchymal transition in vitro. 74 
 c-Myc is an oncogene overexpressed in 50% of all malignancies, including colitis-75 
associated cancer (CAC).  76 
 What are the new findings? 77 
 BVES promoter hypermethylation is present in CAC and distant uninvolved mucosa. 78 
 BVES is underexpressed in patients with CAC compared to normal colonic tissue. 79 
 Deletion of Bves promotes colitis-associated tumor multiplicity and dysplasia. 80 
 BVES directs the PR61α-PP2A complex to target c-Myc for proteasomal destruction. 81 
How might it impact on clinical practice in the foreseeable future?  82 
 BVES promoter hypermethylation status is a potential biomarker to identify UC 83 
patients at risk for cancer. 84 
 Our studies demonstrate a new mechanism for regulation of c-Myc, an oncogene that 85 
is dysregulated in numerous malignancies. 86 
 BVES plays a key role in maintaining the integrity of the colonic mucosa and 87 
protecting from inflammatory carcinogenesis, and may represent a therapeutic target 88 
in CAC. 89 
 90 
  91 
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INTRODUCTION 92 
Chronic inflammation promotes the development of colorectal cancer (CRC)1,2. 93 
Patients with inflammatory bowel disease (IBD), for example, have an elevated risk of 94 
developing CRC3, particularly those who have extensive disease or long disease 95 
duration4. Although the pathogenesis of inflammatory carcinogenesis remains unclear, at 96 
least one component of malignant degeneration is thought to be disruption of intestinal 97 
epithelial function as a consequence of chronic inflammation5,6. Indeed, pathologic 98 
changes in adherens and tight junction proteins have been described in colitis and colitis-99 
associated cancer (CAC)6–8. In addition to providing junctional integrity between cells, 100 
adherens and tight junctional complexes also transduce extracellular signals to direct 101 
intracellular programs (“outside-in” signaling9), such as those controlling cellular 102 
proliferation and differentiation. For example, E-cadherin can sequester β-catenin at the 103 
cell membrane, preventing its nuclear localization and transcriptional activity10. Given 104 
that dysregulation of junctional proteins commonly occurs in CAC, understanding their 105 
function in normal biology may yield clues to how their dysfunction promotes 106 
carcinogenesis.   107 
Blood vessel epicardial substance (BVES/POPDC1) is a tight junction-associated 108 
protein often silenced in carcinomas secondary to promoter hypermethylation11–13. 109 
Restoring BVES expression in CRC cell lines promotes epithelial-like morphology and 110 
decreases proliferation, migration, invasion, xenograft tumor growth, and metastasis, 111 
together indicating broad regulatory capabilities11. Conversely, knockdown of BVES in 112 
epithelial-like cells induces a mesenchymal-like phenotype characterized by increased 113 
proliferation, altered morphology, and disorganized cell-cell contacts11. Yet how BVES 114 
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 6 
regulates these phenotypes is incompletely understood. Indeed, while several BVES 115 
interacting proteins have been identified11, their known functions do not explain fully the 116 
role of BVES in maintaining epithelial phenotypes. Moreover, how BVES contributes to 117 
tumor development has not been tested using genetic approaches.  118 
The transcription factor c-Myc is commonly overexpressed in cancer14,15 and 119 
regulates proliferation, differentiation, apoptosis, and epithelial-to-mesenchymal 120 
transition16. In mouse models of sporadic CRC, decreased c-Myc levels reduce Apc-121 
driven tumorigenesis17. In IBD, c-Myc is overexpressed in both inflamed tissues and 122 
CAC tumors18, and network analysis of CAC samples indicated that c-Myc dysregulation 123 
functionally contributes to CAC progression19. c-Myc levels are also increased in 124 
experimental models of inflammatory carcinogenesis, such as the azoxymethane 125 
(AOM)/dextran sodium sulfate (DSS) mouse model of CAC20. Yet the processes 126 
responsible for c-Myc dysregulation in inflammatory carcinogenesis remain unidentified. 127 
To date, a complex network of proteins—including protein phosphatase 2A (PP2A), 128 
Axin1, and GSK3β—has been identified that regulates c-Myc protein levels by 129 
modifying the phosphorylation status of c-Myc at two residues, threonine 58 (T58) and 130 
serine 62 (S62)21. Ubiquitylation of c-Myc is initiated by phosphorylation at T58, leading 131 
to its ultimate degradation. Given the prominent role of c-Myc in driving oncogenic 132 
programs, understanding mechanisms that control PP2A dephosphorylation of c-Myc 133 
may identify new therapeutic targets in inflammatory carcinogenesis.  134 
 Here we report that BVES is an important regulator of inflammatory 135 
carcinogenesis programs and promotes c-Myc degradation through an interaction with the 136 
PR61α-PP2A complex. We observed that BVES is reduced in human CAC samples, and 137 
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 7 
further that the BVES promoter was hypermethylated within the tumors and at distant 138 
unaffected mucosa, suggesting a field effect. Using the AOM/DSS inflammatory 139 
carcinogenesis model, we determined that Bves-/- mice demonstrate greater tumor 140 
incidence and multiplicity as well as a higher degree of dysplasia and intratumoral 141 
proliferation. Furthermore, molecular analysis of Bves-/- tumors revealed increased c-Myc 142 
protein and signaling activity. c-Myc protein was also elevated in intestinal crypts from 143 
Bves-/- mice. In line with in vivo results, knockdown of BVES in vitro increased c-Myc 144 
stability and consequently increased expression of key c-Myc targets ODC and CAD. 145 
Conversely, BVES overexpression reduced c-Myc stability and increased c-Myc 146 
ubiquitylation. Using a yeast two-hybrid (Y2H) screen, we identified PR61α, the PP2A 147 
regulatory subunit critical for c-Myc degradation, as a BVES-interacting protein, and 148 
show that this interaction is required for BVES to modulate cellular c-Myc levels. Thus, 149 
we demonstrate that BVES coordinates PR61α-containing PP2A phosphatase complexes 150 
to restrict c-Myc protein levels and that BVES is a key suppressor of inflammatory 151 
carcinogenesis whose promoter methylation status may define patients with ulcerative 152 
colitis (UC) at risk for colon cancer.   153 
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MATERIALS AND METHODS 154 
Mice, treatments, and analysis 155 
AOM and DSS were prepared as previously described22. Bves-/- mice have been 156 
previously described23. Detailed protocols can be found in the Supplementary Materials 157 
and Methods Section.  158 
 159 
BVES promoter methylation analysis 160 
Tissue samples were obtained from colectomy specimens from individuals without UC, 161 
individuals with UC but without dysplasia or cancer, and UC patients with high-grade 162 
dysplasia and/or colon cancer.  Clinical information is described in online 163 
supplementary table 1. Detailed protocols regarding epithelial isolation, methylation 164 
array, and pyrosequencing can be found in the Supplementary Materials and Methods 165 
Section. 166 
 167 
See Supplementary Materials and Methods for detailed methods regarding cell culture 168 
experiments, RNA scope, promoter methylation analyses, and mouse analysis. 169 
 170 
  171 
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 9 
RESULTS 172 
BVES is downregulated and its promoter is hypermethylated in CAC 173 
As BVES is underexpressed via promoter hypermethylation in CRC11, we asked 174 
whether the BVES promoter was also hypermethylated in CAC. Therefore, we analyzed 175 
BVES methylation status in an Infinium HumanMethylation450 array screen of IBD 176 
samples. The samples consisted of control patients (Control—No UC), patients with UC 177 
who did not have cancer (UC—no HGD/CAC), and two different types of samples from 178 
patients with UC who had colon cancer: the remote, non-malignant tissue (UC—179 
concurrent HGD/CAC) and tissue with high-grade dysplasia and/or cancer 180 
(HGD/CAC). These analyses demonstrated that the BVES promoter was unmethylated in 181 
the controls–No UC (0.1% + 0.016%), moderately methylated in UC–no HGD/CAC 182 
(16% + 4.7%), and hypermethylated in the HGD/CAC among patients with colitis-183 
associated carcinoma (HGD/CAC, 53% + 2.6%) (figure 1A). Furthermore, remote non-184 
neoplastic, mucosal samples (UC-Concurrent HGD/CAC) from the same patients who 185 
had CAC (HGD/CAC) were hypermethylated (50% + 2.6%) to a similar degree as that 186 
observed in cancerous tissue. Interestingly, these results suggest that BVES promoter 187 
methylation may represent a field effect in CAC and that BVES promoter methylation 188 
status may identify UC patients with concurrent malignancy. To confirm the results 189 
derived from the HM450 methylation array studies, we pyrosequenced the BVES 190 
promoter in the same samples and again demonstrated low levels of methylation in the 191 
UC—no HGD/CAC cases, and higher methylation in both the UC—concurrent 192 
HGD/CAC and HGD/CAC cases (figure 1B).  193 
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 10
It is possible that BVES promoter methylation, while increased, may not be 194 
sufficient to silence its expression. To determine whether BVES promoter methylation 195 
indeed reduced its transcription, we tested whether BVES mRNA was downregulated in 196 
CAC using high resolution in situ hybridization (RNAScope24) in a tissue microarray 197 
consisting of normal, UC, and CAC samples. BVES mRNA levels were low, but 198 
consistently present in normal colonic epithelial cells (figure 1C). In UC and CAC 199 
samples, however, BVES message was rarely detected and quantification of epithelial 200 
staining indicated a 5-fold decrease (p<0.001). Taken together, BVES RNA expression is 201 
downregulated in both UC and CAC, most likely due to promoter hypermethylation. 202 
Furthermore, as the BVES promoter is hypermethylated in both tumor and non-malignant 203 
mucosa in patients with CAC, BVES promoter methylation may serve as a biomarker 204 
associated with dysplasia or neoplasia in patients with IBD. 205 
Bves loss promotes CAC development  206 
While BVES underexpression was consistently observed in human CAC, these 207 
studies do not establish whether BVES loss actively promotes tumorigenesis. Therefore, 208 
we used mouse genetic approaches combined with the AOM/DSS model (figure 2A) to 209 
determine if BVES loss contributed to inflammatory tumorigenesis. While Bves was 210 
expressed at baseline in the murine colon at both the RNA and protein levels (see online 211 
supplementary figure 1), transcriptome profiling of AOM/DSS-induced tumors in WT 212 
mice showed a 5-fold decrease in Bves transcripts (figure 2B), mirroring the results 213 
observed in human CAC. As expected, we also observed changes in other tight junction 214 
constituents, supporting previous reports of tight junctional dysregulation in colitis and 215 
CAC25. We confirmed that Bves message was decreased in AOM/DSS tumor tissue by 216 
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qPCR in an independent sample set (figure 2B). Interestingly, Bves message also 217 
decreased in AOM/DSS treated non-malignant tissue compared to normal colons (figure 218 
2B), again suggesting a field effect in inflammatory carcinogenesis. As a result, we 219 
hypothesized that complete loss of Bves might promote inflammatory carcinogenesis.  220 
To test the effect of Bves loss in CAC, we compared WT and Bves-/- mice 221 
subjected to the same inflammatory carcinogenesis protocol. We first observed that Bves-222 
/-
 mice lost a greater fraction of body weight compared to WT mice, most notably during 223 
cycle 3 (figure 2C), suggesting increased sensitivity to AOM/DSS treatment. Indeed, 224 
endoscopy one-week prior to sacrifice demonstrated increased tumor multiplicity in Bves-225 
/-
 mice (figure 2D) and this was confirmed at necropsy where we observed 100% tumor 226 
penetrance in Bves-/- mice compared to 60% in WT mice (figure 2E). Bves-/- mice also 227 
demonstrated increased tumor multiplicity (6.5 ± 0.6 tumors per Bves-/- mouse vs. 2.2± 228 
0.5 tumors per WT mouse, p<0.001), and tumor size (figure 2E). Furthermore, Bves-/- 229 
tumors exhibit more advanced dysplasia compared to WT tumors (figure 2F). Control 230 
mice treated with three cycles of DSS-only or a single AOM injection did not develop 231 
tumors during this time-frame (data not shown). Taken together, these results suggest that 232 
BVES underexpression in CAC functionally contributes to inflammatory carcinogenesis. 233 
Increased proliferation and enhanced Wnt activation in Bves-/- tumors 234 
 235 
To identify BVES-directed mechanisms responsible for modifying tumorigenesis, 236 
we examined proliferation and apoptosis in the tumors of AOM/DSS treated Bves-/- mice. 237 
Proliferation, as measured by phospho-histone H3 staining, was increased in Bves-/- 238 
tumors (figure 3A). Conversely, staining for cleaved caspase-3 indicated no difference in 239 
intratumoral apoptosis between Bves-/- and WT mice (see online supplementary figure 240 
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2). As Wnt activation can drive proliferation, we postulated that Wnt signaling might be 241 
perturbed in Bves-/- tumors. β-catenin dysregulation is a key indicator of hyperactive Wnt 242 
signaling26, and β-catenin is also a mutational target in DMH/DSS inflammatory 243 
carcinogenesis, resulting in increased levels and altered subcellular distribution27. 244 
Therefore, we analyzed β-catenin by immunohistochemistry and observed excessive 245 
cytoplasmic and nuclear β-catenin localization in Bves-/- tumors compared to WT tumors 246 
(figure 3B). While these results suggested hyperactive Wnt signaling in Bves-/- tumors, 247 
we confirmed this by RNA-seq analysis, which indicated upregulation of established Wnt 248 
targets, such as Mmp7, Wisp2, and Rspo4 (figure 3C), in Bves-/- tumors. Ingenuity 249 
Pathway Analysis (IPA)28 of the RNA-seq data set also indicated hyperactive Wnt 250 
networks, such as β-catenin and Tcf. Finally, immunoblotting demonstrated greater 251 
expression of cyclin D1 and c-jun, two well-characterized Wnt target genes29,30, in Bves-/- 252 
tumors (figure 3D). While previous experiments demonstrated that BVES could regulate 253 
Wnt signaling using in vitro, cell-based assays11, these findings provide the first in vivo 254 
and genetic evidence supporting the hypothesis that BVES regulates Wnt activity. 255 
BVES regulates c-Myc degradation  256 
 As c-Myc is a bona-fide Wnt transcriptional target17, has been identified as a 257 
potential biomarker in patients with IBD at risk for CAC19, and is overexpressed in 258 
AOM/DSS tumors20, we postulated that c-Myc was dysregulated in Bves-/- tumors. 259 
Indeed, IPA analysis of intratumoral transcriptomes identified causal dysregulation28 of 260 
c-Myc networks (see online supplementary figure 3A). While analysis of RNA-seq 261 
datasets showed only a modest increase in c-Myc transcripts in Bves-/- tumors compared 262 
to WT tumors (see online supplementary figure 3B), immunohistochemical staining for 263 
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c-Myc demonstrated an increase in both total c-Myc protein (figure 4A) and 264 
transcriptionally active, phosphorylated serine 62 c-Myc species in Bves-/- tumors (see 265 
online supplementary figure 4). Interestingly, immunoblotting in tumor-adjacent 266 
mucosa also showed higher c-Myc levels in Bves-/- colons, which suggested c-Myc was 267 
increased prior to tumor formation and that BVES might regulate c-Myc levels in the gut 268 
at baseline (figure 4B). To test this, we isolated crypts from untreated Bves-/- and WT 269 
mice and observed greater c-Myc protein in Bves-/- samples (figure 4C). Consistent with 270 
elevated c-Myc, qPCR for Ornithine decarboxylase (Odc), a c-Myc transcriptional target, 271 
indicated a 4-fold increase in Bves-/- colons (see online supplementary figure 5). We 272 
also observed increased mRNA of c-Myc targets Odc and E2f transcription factor 2 273 
(E2f2) (figure 4D) in “mini-gut” 3D cultures, demonstrating that BVES regulation of c-274 
Myc activity was epithelial cell-autonomous. 275 
 As we observed increased c-Myc protein in Bves-/- tumors, we postulated that 276 
BVES could regulate c-Myc protein stability. Three cell lines—HEK 293T (non-277 
malignant cell line), Caco2 (CRC cell line that can form a polarized epithelium), and 278 
HCE (Human Corneal Epithelial)—which all express BVES (supplementary figure 6)11 279 
were used for BVES knockdown experiments. In all three cell lines, BVES RNAi 280 
increased c-Myc protein levels (figure 5A and supplementary figure 7). In addition to 281 
increasing total c-Myc protein, we also observed that BVES knockdown reduced T58 282 
phosphorylation, a key post-translational modification which signals for c-Myc 283 
degradation by the ubiquitin-proteasome system (figure 5A). This increase in c-Myc was 284 
functionally relevant as transcript levels of c-Myc targets ODC and Carbamoyl-285 
Phosphate Synthetase 2 Aspartate Transcarbamylase and Dihydroorotase (CAD) were 286 
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increased with BVES knockdown (figure 5B). Furthermore, knockdown of BVES 287 
doubled c-Myc half-life compared to non-targeting control samples (figure 5C). 288 
Conversely, overexpressing BVES reduced c-Myc protein levels, increased T58 c-Myc 289 
species (figure 5D), dampened c-Myc transcriptional activation of the c-Myc responsive 290 
E2F2 reporter (see online supplementary figure 8), and decreased c-Myc protein half-291 
life (figure 5E, lower panel). We then tested whether BVES could regulate c-Myc 292 
ubiquitylation, a central post-translational event targeting its destruction. Indeed, by 293 
overexpressing BVES we observed increased c-Myc polyubiquitylation (figure 5F). 294 
Moreover, inhibiting the proteasome using MG132 blocked BVES-induced reduction of 295 
c-Myc (figure 5F). Hence, our results suggest that BVES promotes the post-translational 296 
degradation of c-Myc. 297 
BVES interacts with PR61α, PP2Ac, and c-Myc 298 
To identify a molecular mechanism by which BVES orchestrates c-Myc 299 
degradation, we conducted a Y2H screen to define the BVES interactome. 300 
Characterization of this interactome using the PANTHER (Protein ANalysis THrough 301 
Evolutionary Relationships) Classification System31 identified a number of biologic 302 
processes influenced by BVES (figure 6A). Interestingly, the screen identified that 303 
BVES interacted with four of the five members of the B’ family of PP2A regulatory 304 
subunits (PPP2R5A, PPP2R5B, PPP2R5D, and PPP2R5E). PPP2R5A, also known as 305 
PR61α, is a key regulator of PP2A mediated c-Myc dephosphorylation. PR61α directs 306 
the heterotrimeric PP2A complex, consisting of a regulatory, catalytic, and structural 307 
subunit, to associate with doubly phosphorylated (T58/S62) c-Myc and dephosphorylate 308 
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S62, resulting in increased levels of monophosphorylated T58 c-Myc species, which 309 
signals c-Myc to be degraded by the proteaosome32.  310 
The BVES:PR61α interaction was then confirmed by directed Y2H (figure 6A) 311 
and by exogenous and endogenous co-immunoprecipitation in HEK 293T cells (figure 312 
6B and C). If BVES were interacting with PR61α to promote c-Myc degradation, we 313 
hypothesized that BVES would complex with both the PP2A catalytic subunit (PP2Ac) 314 
and c-Myc, which we then demonstrated by co-immunoprecipitation (figure 6D and E 315 
and see online supplementary figure 9). We further used the proximity ligation assay 316 
(PLA) and confirmed interaction of both exogenous and endogenous BVES with 317 
endogenous PR61α and c-Myc (figure 6F). Overall, these data indicate that BVES 318 
complexes with c-Myc, PR61α, and the PP2A catalytic subunit. 319 
BVES is essential for PR61α-mediated c-Myc degradation 320 
PP2A dephosphorylation of S62 requires c-Myc to be phosphorylated at residue 321 
T5833. If BVES reduces c-Myc through PP2A, we reasoned c-MycT58A, a c-Myc mutant 322 
resistant to T58 phosphorylation, would escape BVES-induced degradation.  Indeed, 323 
BVES expression consistently reduced c-MycWT but had no effect on c-MycT58A (figure 324 
7A). We next hypothesized that knockdown of BVES would ablate PR61α-PP2A 325 
induced c-Myc degradation. Overexpression of PR61α reduced c-Myc protein subtly but 326 
consistently as previously reported32 (figure 7B; compare lane 1 and 3). Knocking down 327 
BVES, however, rescued PR61α-induced degradation (figure 7B; compare lanes 3 and 328 
4). We then tested whether BVES could enhance PR61α-mediated c-Myc degradation, 329 
and indeed, overexpression of BVES and PR61α substantially reduced c-Myc protein 330 
compared to PR61α or BVES alone (figure 7C; compare lane 4 to 2 or 3). 331 
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We then sought to determine whether BVES requires PR61α to degrade c-Myc. 332 
For these experiments we first mapped the BVES:PR61α interaction domain by serial 333 
deletions to the carboxy-terminus of BVES. Deleting the carboxy-terminal 30 residues, 334 
but not the last 15 residues, disrupted the BVES:PR61α interaction as demonstrated by 335 
Y2H and by co-IP, thus mapping the interaction domain to residues 330-345 (figure 7D). 336 
Importantly, this uncoupling mutant (BVES-330) demonstrated reduced affinity for c-337 
Myc (figure 7E) and was unable to reduce c-Myc levels (figure 7F), indicating BVES 338 
indeed requires interaction with PR61α to regulate c-Myc. Overall, our results 339 
demonstrate that BVES, through PR61α, promotes c-Myc dephosphorylation, 340 
destabilization, and destruction, and thus provides mechanistic insight into one manner 341 
by which BVES may contribute to inflammatory carcinogenesis.   342 
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DISCUSSION 343 
We, and others, have shown that BVES is underexpressed in gastrointestinal 344 
cancers and that restoration of BVES in cancer cell lines induces epithelial features. Here 345 
we provide the first genetic evidence that BVES modifies cancer phenotypes, as we 346 
demonstrate that mice lacking Bves have increased tumor multiplicity and dysplasia after 347 
establishment of inflammatory carcinogenesis. Further, we show Bves-/-
 
tumors have 348 
increased c-Myc protein resulting in activation of c-Myc regulated networks. Moreover, 349 
we identify that BVES interacts with PR61α, a key regulatory subunit of the PP2A 350 
phosphatase complex, and promotes PP2A-mediated c-Myc dephosphorylation leading to 351 
c-Myc degradation. Uncoupling the BVES:PR61α interaction blocks BVES-dependent 352 
reduction of cellular c-Myc levels. To our knowledge, this is the first junctional-353 
associated protein identified that regulates post-translational c-Myc status. The potential 354 
clinical relevance is demonstrated as we observed that BVES is downregulated in CAC 355 
likely secondary to promoter methylation. However, perhaps more importantly, we 356 
establish that the BVES promoter is also aberrantly methylated in distant, normal 357 
appearing tissues in patients with CAC/HGD—suggesting a field effect. Thus, our 358 
findings not only reveal that deletion of BVES promotes CAC, but also that BVES 359 
promoter methylation status may be a clinically important surrogate marker of colitis-360 
associated dysplasia or CAC in IBD patients.  361 
Chronic colitis has been shown to accelerate genome-wide methylatio  changes34; 362 
it has been hypothesized that this greater rate of methylation contributes to the increased 363 
cancer risk in patients with colitis by silencing tumor suppressors. Understanding how 364 
methylation broadly affects inflammatory tumorigenesis is important to design therapies 365 
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and screening strategies for IBD patients. Our report specifically identifies that the BVES 366 
promoter is hypermethylated in UC patients who have CAC. Interestingly, BVES 367 
promoter hypermethylation is observed not only in the cancerous tissue, but also in the 368 
non-malignant mucosa in these patients. Currently, the standard method of cancer 369 
screening in IBD patients, who are at up to a 10-fold elevated risk of developing CAC1, is 370 
surveillance colonoscopy performed with the hope that cancer will be detected at an 371 
early, treatable stage. Yet the detection of neoplasia in the colon can be challenging in 372 
individuals with IBD, as the lesions are frequently flat and difficult to detect in a 373 
background of acute and chronic inflammatory changes. Our data suggest that aberrant 374 
BVES promoter methylation may be a useful biomarker for the presence of CAC, or even 375 
dysplasia, and that measuring BVES promoter methylation status could serve as a 376 
clinically useful tool to identify patients at risk for colon dysplasia or cancer. 377 
While the molecular pathogenesis of CAC remains incompletely understood, 378 
recent work has shown the importance of NF-κB signaling35, the intestinal microbiota36, 379 
the tumor microenvironment37, and the innate immune system38 in regulating 380 
inflammatory tumorigenesis. A growing body of evidence also supports the important 381 
role of epithelial junctional constituents in inflammation and CRC. For example, mice 382 
expressing a dominant negative N-cadherin display disrupted adherens junctions and 383 
develop severe inflammation and colitis-associated dysplasia39. Likewise, knocking out 384 
Junctional adhesion molecule (Jam-A) results in a dramatic increase in susceptibility to 385 
DSS-induced colitis8. Here we show that deletion of Bves, a tight junction-associated 386 
protein, augments inflammatory carcinogenesis. Indeed, loss of BVES appears to 387 
increase tumor initiation and progression. We postulate that this is likely due to dual 388 
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regulation of Wnt signaling and c-Myc protein degradation. Our results further strengthen 389 
the concept that junctional constituents are important regulators of colitis-induced tumor 390 
initiation and progression.  391 
In the last decade, BVES has been shown to regulate a variety of cellular 392 
processes. For example, a Y2H screen of a mouse heart library identified an interaction 393 
between BVES and GEFT, a guanine nucleotide exchange factor40. Indeed, it was shown 394 
that expression of BVES modulated cell shape and locomotion, thus linking BVES to 395 
Rho-family GTPase signaling40. BVES has also been shown, via an interaction with ZO-396 
1, to regulate GEF-H1-mediated RhoA activity11. More recently, it was reported that 397 
BVES plays a regulatory role in cardiac pacemaking through binding of cAMP and 398 
interacting with potassium channel TREK-141. Further, BVES interacts with CAV3, a 399 
caveolin expressed in the muscle tissue, and cardiac myocytes in Bves-/- mice have altered 400 
calveolar number and size42. Thus, BVES, through scaffolding with protein complexes, 401 
regulates a wide variety of basic, yet essential, cellular processes.  402 
Our results now expand the known regulatory roles of BVES to include 403 
maintaining appropriate c-Myc protein levels. We show that BVES, through its 404 
interaction with the PR61α-containing PP2A phosphatase complex, can promote c-Myc 405 
degradation and that silencing BVES prevents PR61α-induced degradation of c-Myc. 406 
Moreover, mutating BVES so that it is unable to associate with PR61α renders BVES 407 
unable to initiate c-Myc destruction. The post-translational regulation of c-Myc requires 408 
coordination of numerous proteins to modify its phosphorylation and ubiquitylation 409 
status21. Precisely how BVES coordinates the PR61α-PP2A complex remains to be 410 
understood, but given that analysis of BVES structure shows no apparent enzymatic 411 
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motifs in BVES, it is likely that BVES acts as a scaffold allowing for complex formation, 412 
similar to AXIN121. Interestingly, in addition to the membranous staining of the 413 
BVES:PR61α complex, there also appears to be peri-nuclear and cytoplasmic 414 
localization (figure 6F), which is consistent with previous reports describing the dynamic 415 
subcellular localization of BVES and its family members43. The PP2A family has been 416 
associated with tight junctional complexes regulating cellular permeability, but their 417 
exact role remains controversial44. BVES may bridge PP2A complexes to tight junctions 418 
and our report adds a new molecular mechanism for “outside-in” signaling in the 419 
epithelium.  420 
Because c-Myc regulates thousands of genes, even subtle changes in c-Myc 421 
expression can have profound effects on cellular transcriptomes that promote 422 
tumorigenesis45. Indeed, strict regulation of c-Myc is an important component of 423 
homeostasis, and this is particularly true in the intestine. Acute expression of c-Myc, for 424 
example, dramatically expands the intestinal crypts and results in loss of differentiated 425 
cells46. Moreover, it has been shown that c-Myc is essential for Apc-mediated intestinal 426 
tumorigenesis17. Thus, BVES may serve as an important suppressor of inflammatory 427 
tumorigenesis via attenuating excessive c-Myc levels. More broadly, BVES could act as a 428 
regulator of c-Myc in a variety of tissues, as BVES is expressed in most epithelial tissues, 429 
such as lung, stomach, and breast, and its downregulation or promoter hypermethylation 430 
has been documented in diverse epithelium11–13.  431 
Taking our data together, one can envision a model in which chronic 432 
inflammation leads to BVES promoter hypermethylation, resulting in suppression of 433 
BVES transcription and reduced cellular protein levels. Loss of BVES impairs PR61α 434 
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directed PP2A dephosphorylation of c-Myc, thus favoring increased cellular pools of c-435 
Myc, a potent oncogene, likely, in cooperation with other oncogenic events, contributing 436 
to tumor progression (figure 8). 437 
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Legends 569 
Figure 1 A field effect of BVES promoter hypermethylation in colitis-associated cancer. 570 
(A) Average BVES promoter methylation status in the indicated sample from the Infinium 571 
HumanMethylation 450 Array. Methylation was measured in four sample types: colon 572 
epithelia from patients who did not have UC (Control—No UC); colon epithelia from UC 573 
patients who did not have dysplasia or carcinoma (UC—no HGD/CAC); non-malignant 574 
colon epithelia from UC patients (UC—concurrent HGD/CAC) and malignant colon 575 
epithelia (HGD/CAC) from UC patients who had dysplasia/carcinoma. Control—No UC, 576 
n=17; UC—no HGD/CAC, n=11; UC—concurrent HGD/CAC, n=10; HGD/CAC, n=10. 577 
**p<0.01. 578 
(B) Pyrosequencing at four sequential CpG dinucleotides in the BVES promoter. Each 579 
shape represents a separate individual, with mean methylation values depicted with black 580 
bars. ***p<0.001. 581 
(C) Representative images of high-resolution in situ (RNAscope™) analysis of BVES 582 
message in normal colons (n=11), UC (n=13), and CAC (n=19). Right: Quantification of 583 
BVES expressing epithelial cells per tissue microarray core. Size standard=50 microns. 584 
***p<0.001 585 
 586 
Figure 2 BVES modifies inflammatory carcinogenesis.  587 
(A) Schematic of AOM/DSS protocol and timeline. Mice were injected with 7.5 mg/kg of 588 
AOM and treated with 2.5% DSS at the indicated time. 589 
(B) Left: Heat map of RNA-seq data derived from WT colons (n=3) and WT AOM/DSS 590 
tumors (n=3). Red indicates genes increased and green indicates genes decreased in 591 
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tumors compared to normal colon. Right: qPCR of Bves message levels in normal colons 592 
(Normal, n=5), non-malignant AOM/DSS treated colon (NM, n=5) and AOM/DSS tumor 593 
(Tumor, n=6). Tissue harvested from WT mice after AOM/DSS treatment. ***p<0.001. 594 
(C) Weights of Bves-/- and WT mice during AOM/DSS treatment. Weights are presented 595 
as fraction of initial weight. Bves-/- (male: n=8, female: n=7) and WT (male: n=5, female: 596 
n=10). *p<0.05, ***p<0.01, ***p<0.001. 597 
(D) Representative colonoscopy images of WT and Bves-/- colons after the second cycle 598 
of DSS treatment. Right: Quantification of tumor multiplicity by endoscopy assessment.  599 
(E) Tumor incidence, multiplicity, and size distribution at necropsy in WT and Bves-/- 600 
mice. Blue = female mice, black = male mice.*p<0.05, ***p<0.001. 601 
(F) Left: Representative H&E stained sections demonstrating the histologic features of 602 
WT and Bves-/- tumors. Size standard=100 microns. Right: Blinded histological scoring of 603 
degree of dysplasia of tumors from WT and Bves-/- mice. Graph represents percentage of 604 
mice with intratumoral low or high-grade dysplasia.  605 
 606 
Figure 3 Dysregulated Wnt signaling in Bves-/- tumors. 607 
(A) Left: Representative images of phospho-histone H3 (pH3) immunohistochemistry in 608 
WT and Bves-/- tumors. Size standard=50 microns. Right: Quantification of pH3 positive 609 
cells per tumor high power field (HPF). Data is presented as the mean number of positive 610 
cells per tumor HPF per mouse. At least five HPF per mouse were scored. Student’s t 611 
test, *p<0.05. 612 
(B) Left: H&E stained sections, size standard=50 microns. Middle: Representative 613 
images of β-catenin immunohistochemistry, low magnification, size standard=50 614 
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microns. Right: β-catenin immunohistochemistry, high magnification, size standard=20 615 
microns. Far right: Quantification of intratumoral β-catenin immunohistochemistry. An 616 
index was employed to quantify extent of nuclear and cytoplasmic β-catenin staining. 617 
This index is generated by multiplying the staining intensity (on a scale of 100-500) by 618 
percentage of the cells demonstrating nuclear staining. For example, a score of 500 619 
indicates a field that demonstrated very intense nuclear β-catenin stain while a score of 620 
100 indicates a fi ld that has weak nuclear β-catenin staining. Data is presented as the 621 
mean score per tumor HPF per mouse. At least five HPF per mouse were scored. 622 
(C) Wnt target genes upregulated in Bves-/- tumors identified in RNA-seq dataset (WT, 623 
n=3; Bves-/-, n=3).  624 
(D) Immunoblot of Cyclin D1 and c-jun in Bves-/- and WT tumors. β-actin was used as a 625 
loading control.  626 
 627 
Figure 4 c-Myc signaling is dysregulated in Bves-/- mice in inflammatory carcinogenesis. 628 
(A) Left: Representative images of immunohistochemistry for intratumoral c-Myc. Right: 629 
quantification of c-Myc positive cells per tumor high power field (HPF). HPFs were 630 
scored according to an index from 1-4 (a score of 1 denotes less than 25% of positive 631 
cells per HPF; a score of 2 denotes 25-50%; a score of 3 denotes 50-75%; a score of 4 632 
denotes 80-100%). Data is presented as the mean score per tumor HPF per mouse. At 633 
least five HPF per mouse were scored. Student’s t test, *p<0.05. Size standard=50 634 
microns 635 
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(B) Immunoblot of c-Myc in WT and Bves-/- normal adjacent colons. Blots were imaged 636 
using the LiCor Odyssey system and quantified using Image Studio analysis. Student’s t 637 
test, p<0.05. 638 
(C) Immunoblot of c-Myc in WT (n=3) and Bves-/- (n=3) intestinal crypts.  639 
(D) qPCR for Odc and E2f2 in enteroid cultures Student’s t test, *p<0.05.  640 
In all western blots, β-actin served as loading control. 641 
 642 
Figure 5 BVES regulates c-Myc stability and activity.  643 
(A) c-Myc and T58 phospho-c-Myc protein levels after BVES knockdown in HEK 293T 644 
(left) or Caco2 (right) cells after 48 hr serum starvation.  645 
(B) qRT-PCR assay for c-Myc targets ODC and CAD following BVES knockdown in the 646 
indicated cell lines. Data are presented as mean ±SEM and in triplicates. *p<0.05, 647 
**p<0.01. 648 
(C) Cycloheximide treatment (100 µg/ml) of HEK 293T cells with and without Bves 649 
knockdown followed by immunoblotting for c-Myc.  650 
(D) c-Myc and T58 phospho-c-Myc protein levels after overexpression of V5:BVES in 651 
HEK 293T cells.  652 
(E) HEK 293T cells co-transfected with HA:c-Myc and V5:BVES were then treated with 653 
cycloheximide (100 µg/ml) followed by immunoblotting for the indicated protein.  654 
(F) Left: His:Ubiquitin and HA:c-Myc were co-transfected into HEK 293T cells along 655 
with V5:BVES. Cells were treated with proteasome inhibitor MG132 (20 µm) for 4 hours 656 
before His:Ubiquitin complexes were immunoprecipitated and resolved by SDS-PAGE. 657 
Ubiquitylated HA:c-Myc complexes were visualized by immunoblotting (Ub-c-Myc). 658 
Total ubiquitylated protein (Total ub) was examined as a control. Right: HEK 293T cells 659 
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co-transfected with HA:c-Myc and V5:BVES were treated with proteasome inhibitor 660 
MG132 (20 µm) for 4 hours. Whole cell lysates were analyzed for HA:c-Myc expression.  661 
In all immunoblots, β-actin was used as a loading control.  All experiments were 662 
replicated three times. 663 
 664 
Figure 6 BVES interacts with PR61α, PP2A, and c-Myc. 665 
 666 
(A) PANTHER Biologic Process Analysis of BVES interactome. Inset: Directed yeast 667 
two-hybrid of BVES and PR61α.  668 
(B) Co-immunoprecipitation of exogenous and (C) endogenous PR61α:BVES complexes 669 
in HEK 293T cells.  670 
(D) Co-immunoprecipitation of V5:BVES and HA:PP2Ac or (E) HA:c-Myc.  671 
(F) Left: Proximity ligation assay in HEK 293T cells transfected with V5:BVES. Left: 672 
control, middle: α-PR61α, right: α-c-Myc. Right: Proximity ligation assay in HEK 293T 673 
cells for endogenous protein interactions. Left: control, middle: α-PR61α, right: α-c-674 
Myc. Anti-HA was used as a control in both exogenous and endogenous localization. 675 
Scale bar denotes 10 µm. Red staining is positive signal from the PLA interaction, and 676 
blue staining is DAPI. In all immunoblots blots, β-actin was used to ensure loading 677 
consistency. All experiments were repeated at least two times. 678 
 679 
Figure 7 The BVES:PR61α interaction is required to promote c-Myc degradation.  680 
(A) WT HA:c-Myc or phospho-mutant HA:T58A c-Myc levels after either empty vector 681 
(negative control) or V5:BVES transfection in HEK 293T cells. 682 
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(B) Immunoblotting for HA:c-Myc levels following PR61α overexpression in the setting 683 
of BVES knockdown or (C) when both PR61α and BVES are present HEK 293T cells. 684 
(D) Top: Mapping the PR61α BVES binding interface via directed yeast two-hybrid (Full 685 
length BVES, residues 1-345, 1-330, 1-302, negative control (Neg Ctrl), and positive 686 
control (Pos Ctrl)). Below: Co-immunoprecipitation of the indicated BVES mutants and 687 
PR61α in HEK 293T cells.. 688 
(E) Co-immunoprecipitation of the indicated BVES mutants and HA:c-Myc in HEK 689 
293T cells. 690 
(F) HA:c-Myc protein levels after transfection of the indicated BVES construct in HEK 691 
293T cells. 692 
In all immunoblots, β-actin was used as a loading control.  All experiments were repeated 693 
at least two times. 694 
 695 
Figure 8 Working model of the role of BVES in regulating c-Myc degradation and 696 
colitis-associated cancer development. 697 
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SUPPLEMENTARY MATERIALS AND METHODS 
Mice, treatment, and analysis 
Over the course of two experiments, 15 wildtype (10 female and 5 male) (WT) C57BL/6 
and 15 Bves
-/-
 (7 female and 8 male) mice were treated with 7.5 mg/kg of AOM by 
intraperitoneal injection and placed on 3 cycles of 5 day treatments with 2.5% DSS. Mice 
were between 8-12 weeks of age before AOM treatment. All mice were bred and housed 
in the same facility throughout the duration of the experiment. Both WT and Bves
-/- 
pure 
C57BL/6 colonies were maintained in the same room for a year prior to beginning the 
experiment to ensure a controlled microenvironment. Bves
-/- 
mice were previously 
characterized
1
.
 
All in vivo procedures were carried out in accordance with protocols 
approved by the Vanderbilt Institutional Animal Care and Use Committee. 
  
After the mice were sacrificed, colons were irrigated with phosphate-buffered saline 
(PBS). The colons were then opened longitudinally and rolled orienting the most distal 
region of the colon such that it was located in the inn rmost part of the roll. The tissues 
were then fixed in formalin (1:10 dilution buffered) overnight. The solution was 
subsequently changed to 70% ethanol before standard paraffin-embedding. Five micron 
sections were cut and stained with hematoxylin and eosin (H&E) by the Vanderbilt 
Translational Pathology Shared Resource Core. Proliferation was measured by phospho-
histone H3 (pH3) staining using anti-pH3 at 1:150 (Upstate/Millipore) and incubated 
overnight at 4°C. β-catenin was measured using anti-β-catenin at 1:150 (BD 
Transduction Laboratories). c-Myc was stained using Abcam at 1:1000 (Y69). Phospho-
S62 c-Myc (Abcam #51156) was used at 1:50 dilution and incubated overnight at 4°C. 
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 2 
Vectastain ABC Kit (Vector Laboratories) was used to perform all 
immunohistochemistry reactions. Dewaxing and antigen retrieval processing of sections 
was conducted as previously described
2
.  
 
For intratumoral c-Myc staining, high power fields were scored according to an index 
from 1-4 (a score of 1 denotes less than 25% of positive cells per high power field; a 
score of 2 denotes 25-50%; a score of 3 denotes 50-75%; a score of 4 denotes 75-100%). 
For intratmuoral phosphorylated S62 c-Myc, positive cells per tumor high power field 
were quantified according to an index from 1-5 (a score of 1 denotes less than 20% of 
positive cells per high power field; a score of 2 denotes 20-40%; a score of 3 denotes 40-
60%; a score of 4 denotes 60-80; a score of 5 denotes 80-100%).   Similarly, a β-catenin 
index was employed to quantify the extent of intratumoral nuclear and cytoplasmic 
staining. This index is generated by multiplying the staining intensity (on a scale of 100-
500) by percentage of the cells demonstrating nuclear staining. For example, a score of 
500 indicates a field that demonstrated very intense nuclear β-catenin stain while a score 
of 100 indicates a field that has weak nuclear β-catenin staining. Intratumoral 
proliferation was 7 by staining. Apoptosis and proliferation indices were generated by 
counting the number of positive cells per high-powered field (HPF; 40× objective) within 
each tumor by a blinded observer. In all tumor scoring, the average per mouse is 
presented and at least 5 power fields per animal were counted.  
 
For RNA analysis, colonic tissue from mice was isolated and immediately placed into 
350 µl RNALater (Qiagen) and stored at -80°C. RNA from tissue or cells was isolated 
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 3 
using the RNAEasy kit (Qiagen) according to the manufacturer’s “Animal Tissue” 
protocol. RNA was subsequently stored at -80°C.  
 
For RNA-seq experiments, RNA from WT colons (n=3), Bves
-/-
 colons (n=3), WT tumors 
(n=3), and Bves
-/-
 tumors (n=3) was sequenced by the Vanderbilt Technologies for 
Advanced Genomics (VANTAGE) core facility. Initial raw sequencing data were aligned 
to a reference mouse genome (mm9) using TopHat (version 1.3.1) software
3
. The 
transcript of mouse genome (mm9) was downloaded from UCSC as implemented in the 
Bioconductor package GenomicFeatures. Then the Bioconductor packages Rsamtools 
and DESeq were used to estimate the read count for expression of each gene and to detect 
differentially expressed (DE) genes. For count based gene expression data, DESeq uses a 
model based on the negative binomial distribution which includes a dispersion parameter 
to better estimate variance
4
. The p-values from DESeq were adjusted by Benjamini and 
Hochberg’s method to control false discovery rate (FDR)
5
. 
 
 BVES promoter methylation analysis 
1) Primary Human Tissue Samples 
Fresh frozen epithelial cell layers were isolated from each specimen using the epithelial 
“shake off” technique
6
 and the DNA was extracted using Qiagen DNA extraction kits 
(Qiagen) following the manufacturer’s instructions. DNA was extracted from the 
following groups: 1) 17 control samples of normal colon mucosa from patients who did 
not have UC (Control-No UC) 2) non-neoplastic cells from 11 UC patients without 
cancer/dysplasia (Normal—no HGD/CAC) 3) non-neoplastic cells from 10 UC patients 
with concurrent cancer/dysplasia located at least 20 cm away (Normal—concurrent 
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 4 
HGD/CAC) 4) cancerous or dysplastic cells from 10 UC patients (HGD/CAC). The 
specimens were obtained from the pathology archives at University of Washington 
(Seattle, WA) following protocols approved by the Institutional Review Board.  
 
2) Methylation array analyses 
300 ng of epithelial cell DNA was bisulfite converted using the EZ Meth DNA kit 
following the manufacturer’s instructions (Zymo Research, #D5002). Converted DNA 
was applied to Infinium HumanMethylation450 BeadChips (Illumina) which were then 
processed in the Genomics Shared Resource Core at the Fred Hutchinson Cancer 
Research Center according to the manufacturer’s specifications.  Data was normalized 
and filtered as described by our group previously
7
. Differentially methylated loci (DML) 
were determined after converting beta values, which range from 0.0 (no methylation) to 
1.0 (100% methylation), to M values, where the M value is the log2 ratio of the intensities 
of the methylated probe versus unmethylated probe. For the purposes of this study, we 
were interested in loci that demonstrated both 1) differential methylation between UC—
no HGD/CAC and UC—concurrent HGD/CAC cases and 2) similar methylation 
patterns between UC—concurrent HGD/CAC and HGD/CAC cases. Loci with p 
values ≤ 0.0008 (adjusted p value ≤ 0.260) were considered differentially methylated.  
The differentially methylated probes in the BVES promoter region were   
cg17398252 (located within a CpG island 1500 base pairs upstream from the 
transcription start site), cg25280433 (located within a CpG island in the 5’ UTR/exon 1), 
and cg20624391 (located in a CpG island in 5’ UTR/exon 1). 
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 5 
3) Pyrosequencing of DNA samples 
Pyrosequencing assays were designed to confirm methylation differences seen on the 
HM450 arrays. Assays were designed to target the same promoter CpG island that 
contained the DML from the arrays.  The same DNA samples that were used on the 
HM450 array were used for pyrosequencing, except for one UC—no HGD/CA and one 
UC—concurrent HGD/CAC case, both of which did not have enough DNA remaining for 
these assays. Primers and reaction conditions used have been previously described
8
.  
 
RNAScope 
RNA scope was conducted according to manufacturer’s protocol (ACD, 
www.acdbio.com) with probes directed against BVES (catalog number 410346), positive 
control Hs-PPIB (catalog number 313901), and negative control DapB (catalog number 
310043Tissue microarrays were scanned digitally and uploaded to a digital image hub. 
The percentage of epithelium per core that stained positive was scored and quantified. 
Only cores that stained robustly with the positive control probe were scored. Clinical 
information of specimen is described in Supplementary Table 2. 
 
Enteroid cultures 
Enteroid cultures were derived according to previously published protocols
9
. Briefly, 
eight centimeters of small intestine were dissected, flushed with ice cold phosphate 
buffered saline (PBS), and opened lengthwise. Intestines were quickly rinsed,  dissected 
into 5mm pieces, and washed in 5ml ice cold PBS for 15 minutes at 4
o
C for 15 minutes.  
Fragments were then transferred to 5ml of chelation buffer (2mM EDTA, made fresh in 
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 6 
Dulbecco’s PBS) and rocked for 30 minutes at 4°C. After removing chelation buffer, 5ml 
cold shaking buffer (PBS with 43.3mM sucrose and 54.9mM Sorbitol) was added and 
tissues were gently shaken for 4 minutes to free intestinal crypts. Resulting crypts were 
filtered through a 70µm filter, collected, and plated in Matrigel (Fisher Scientific, CB-
40230C) at a concentration of 600 crypts per 50µl plug. After polymerization, Matrigel 
was overlaid with 500µl mini-gut media (Advanced DMEM/F12, B27, N2, Pen-strep, L-
glutamine, HEPES) supplemented with 50 ng/ml EGF (R&D Systems, 2028-EG-200), 
100 ng/ml Noggin (R&D Systems, 1967-NG-025/CF), 500 ng/ml R-Spondin (Vanderbilt 
Antibody and Protein Resource), and 200 ng/ml WNT3a (R&D Systems, 1324-WN-010). 
Growth media, containing all supplements with the exception of Wnt3a, was replaced 
every 4 days to maintain enteroid cultures. 
 
Yeast two-hybrid assays  
BVES (hgx2637v_pB29) and PR61a (pB20_A-197) constructs were obtained from 
Hybrigenics. Y2H assays were conducted as previously described
10
. 
 
Cell Culture 
Unless otherwise indicated, all HEK 293T and Caco2 cells were cultured in DMEM with 
10% serum and 1% Penn/strep. Polyethylenimine (PEI) at a concentration of 1 g/ml 
was used for all transfection experiments. An empty vector was used to ensure equal 
quantities of cDNA were transfected.  Cycloheximide (Sigma) was used at 100 g/ml 
and cells were lysed at the indicated intervals. MG132 (CalBiochem) was used at 10 M 
for 4 hours for ubiquitylation experiments. 
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 7 
 
BVES was knocked down using siRNA (Santa Cruz, 60295) or shRNA (Mission Sigma 
#143493), and PR61α was knocked down using an shRNA construct (Mission Sigma 
#10507). Scrambled siRNA (Santa Cruz 37007) or shRNA (Mission Sigma #SHC002) 
were used as controls. 
 
Luciferase Report r Assay 
The E2F2 reporter was purchased from Switchgear genomics (ID:S720931).  
The luciferase assays were conducted as previously reported using a SEAP plasmid as a 
transfection control
9
. Briefly, HEK 293T cells were plated in 6 well plates and each 
experimental condition as a technical triplicate.  
 
Immunoprecipitation 
For immunoprecipitation assays, cells were grown in 100-mm cell culture dishes. Once 
desired confluence was reached, cells were rinsed with ice-cold PBS and incubated for 15 
min at 4°C in 1 ml of cell lysis buffer (Sigma) containing 1X Phosphatase inhibitor 
cocktail 2 and 3 (Sigma) and 1X Protease Inhibitor cocktail (Sigma). Samples were 
sonicated for 10 seconds at 4°C. Cellular debris was removed by centrifugation; protein 
concentration was measured by Bradford method. For immunoprecipitation, 
approximately 1 mg of total protein was incubated with 3 µg of the respective antibodies 
overnight at 4°C followed by a 3 hour incubation with 25 µl of protein A/G magnetic 
beads (Millipore). The immunoprecipitates were collected by magnetic separation and 
washed three times with 0.5 ml of cell lysis buffer. Washed beads were suspended in 50 
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 8 
µl of 2X Laemmli buffer and samples were resolved on a reducing 10% SDS-PAGE gel 
and probed with respective antibodies.  
 
Proximity Ligation Assay 
Proximity ligation assays (PLA) were performed according to manufacturer’s protocol 
(Sigma, #DUO92101). Primary antibodies were incubated for 30 minutes in a 37°C 
humidified chamber at 0.250 ug/ul. HA (Invitrogen), V5 (Abcam), c-Myc (cell 
signaling), PPP2R5A (Bethyl labs), BVES (Abcam). 
 
Western Blots 
For western blots, cells were washed with ice-cold PBS before being scraped and 
collected. Cells were pelleted by centrifugation and resuspended in 2X Laemmli buffer 
and boiled for 10 minutes before analysis by SDS-PAGE electrophoresis. Membranes 
were blocked using Odyssey blocking buffer for 30 minutes and then blotted with anti-
PPP2R5A (Bethyl labs, #A300-967A), anti-c-Myc (Cell Signaling #D84C12), anti-V5 
(Abcam #ab27671), anti-His (Abcam #ab18184), or anti-HA (Vanderbilt Antibody and 
Protein Resource). All antibodies were used at 1:1000 concentration in Odyssey blocking 
buffer with 0.1% Tween-20. Primary antibodies were incubated for 1 hour at room 
temperature (RT) before being washed three times in PBS-Tween. LiCor secondary 
antibodies were used at 1:30,000 dilution and incubated for 30 minutes at room 
temperature. Quantification of western blot band intensity was conducted using LiCor 
Image Studio.  
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 9 
Plasmids 
BVES and PR61α expression plasmids were generated using Gateway cloning 
(Invitrogen). pENTR vectors containing either BVES (HsCD00368575, Harvard Plasmid 
Prep) or  PPP2R5A (HsCD00041318, Harvard Plasmid Prep) were shuttled into 
pcDNA3.1 V5/His using LR clonase (Invitrogen). The HA-tagged PP2Ac expression 
plasmid was graciously provided by Peter Howley who deposited the plasmid into 
Addgene repository (plasmid #35005). WT-c-Myc and T58A-c-Myc plasmids were 
previously described
12
.  
 
qPCR 
For quantitative reverse transcription polymerase chain reactions, twenty microliters of 
cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad) from 1 µg of RNA 
per sample. All RT-PCR reactions were carried out using SYBR green reaction mix (Bio-
Rad) according to the manufacturer’s protocol.  
 
The following primers were used to measure expression levels: human CAD: (F: 
AGTGGTGTTTCAAACCGGCAT and R:CAGAGGATAGGTGAGCACTAAGA), 
human ODC (F:TTTACTGCCAAGGACATTCTGG and R: 
GGAGAGCTTTTAACCACCTCAG) and mouse Odc (F: 
AGCAGGCTTCTCTTGGAAC and R: CATGCATTTCAGGCAGGTTA). All qPCR 
reactions were normalized to GAPDH (Human GAPDH, Realtime Primers #3541 and 
Mouse Gapdh, Realtime Primers #7317). 
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 10
Statistical Methods 
Throughout the paper, if more than two groups were being analyzed, a one-way ANOVA 
with New Keuls post-hoc test was used. If only two groups were being compared, a 
Student’s t test was used. In all analyses using IHC, the observer was blinded to slide 
identity, and the slide was scored in an unbiased fashion.  
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Supplementary Figures 1-8 and Supplementary Tables 1-2 
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Supplementary Figure 1 A) Ct values of Gapdh, Bves, 
and E-cadherin mRNA levels in WT mouse colons. B) 
Immunoblot of E-cadherin, BVES and β-actin in mouse 
colons. 
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Supplementary Figure 3 
(A) IPA generated schematic of dysregulated c-Myc network in 
Bves-/- tumors compared to WT tumors. (B) c-Myc mRNA levels 
relative to WT colon.  
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Supplementary Figure 4 
Left: Representative images of immunohistochemistry for intratumoral  
phosphorylated serine 62 c-Myc staining. Right: Quantification of pS62 c-Myc positive 
cells per tumor high power field. High power fields were scored according to an index 
from 1-5 (a score of 1 denotes less than 20% of positive cells per high power field; a 
score of 2 denotes 20-40%; a score of 3 denotes 40-60%; a score of 4 denotes 60-80; 
a score of 5 denotes 80-100%). Each dot represents the average score of each 
mouse per tumor HPF. A minimum of 5 HPF were scored per mouse.  
Student’s t test, *p<0.05. Size standard=50 microns.  
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Supplementary Figure 5 
qPCR for c-Myc transcriptional target Odc in colons of WT and 
Bves-/- mice at baseline. *p<0.05 
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Supplementary Figure 6 
qPCR of BVES mRNA in three human cell lines: HEK 293T, 
Human Corneal Epithelial (HCE), and Caco2. 
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Supplementary Figure 7 
Immunoblot of c-Myc after knockdown of BVES in the Human 
Corneal Epithelial (HCE) cell line using shRNAs. 
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Supplementary Figure 8 
Relative luciferase values of HEK 293T cells co-transfected with 
an E2F2 reporter and an empty vector, HA-c-Myc and/or V5-
BVES. Experiment was performed in technical triplicates and 
replicated twice. **p<0.01 
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Supplementary Figure 9 
HEK 293T cells were transfected with HA:c-Myc and V5:BVES. 
V5:BVES was immunoprecipitated followed by immunoblotting 
for HA:c-Myc. Non-specific IgG was used as a control.  
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Patient Biopsy dx UC NP/P 
biopsy 
dx Location 
Distance to 
Dysplasia(f/
anal verge) Age Gender 
Disease 
Duration(
mo.) PSC? 
Disease 
Activity 
Inflamma
tion 
1 neg NP neg distal  67 M 30 no  3-4+ 
2 neg NP neg distal  70 F 16 no  3-4+ 
3 tumor P tumor distal 0 cm 55 F 20 no  4+ 
4 neg NP neg distal  56 F 10 no   
5 tumor P tumor proximal 0 cm 47 M 8 no  ? 
6 tumor P tumor proximal 0 cm 31 M 10 no  ? 
7 neg NP neg distal  48 M 9 no  3-4+ 
8 neg P neg distal  67 M 30 no  0 
9 neg NP neg distal  41 F 20 no  2-3+ 
10 neg NP neg distal  63 M 39 no   
11 neg NP neg distal  31 M 8 no  3-4+ 
12 neg NP neg distal  49 F 20 no  1-2+ 
13 HGD  P HGD  83 cm 0 cm 36 M 8 yes 
marked 
activity 4+ 
14 HGD P HGD 
(C2)next to rectal 
pieces 0 cm 53 F NA no?  4+ 
15 neg NP neg 7 cm  59 M 0.25  no data active 
16 neg NP neg 14 cm  51 F 20 no no data 3+ 
17 neg NP neg 15 cm  46 F 17 no no data 0 
18 neg P neg 3.4 cm 78.3 cm 36 M 11 yes no data 0 
19 HGD P HGD 92 cm 0 cm 58 M 29 yes 
focal 
activity 0 
20 HGD P HGD 3 cm 0 cm 32 M 16 no active 1+ 
21 HGD P 
LGD
+HGD 19 cm 0 cm 48 M 10 no 
focal 
activity 0 
22 HGD P HGD 4 cm 0 cm 33 M 13 no 
focal 
active 4+ 
23 HGD P HGD 70.4 cm 6.4cm to CA 51 F 13 yes active 1+ 
24 HGD P HGD 31.2 cm 0 cm 33 F 22 no no data  1+ 
25 neg P neg 14.4 cm 18.4 cm 34 M 17 yes active 1+ 
Supplementary Table 1 
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UC Patients With Cancer 
(N=14) 
UC Patients with Dysplasia 
(N=5) 
UC patients 
(N=13) Normal (N=11) 
Average Age (sd) 51.4 + 18.3 53.2 + 15.5 55+ 10.2 60.9 + 11.5 
Gender 6 Males, 8 Females 4 Males, 1 Female 8 Males, 5 Females 5 Males, 6 Females 
BMI 26 + 9.2 n/a n/a 26.6 + 3.1 
Race White (N=14) n/a n/a Black (N=1), White (N=10) 
Tumor Grade 
Grade 1 (N=3), Grade 2 
(N=2), Grade 3 (N=9) n/a n/a n/a 
Location if known 
 
Descending (N=2), 
Transverse (N=2), Left 
(N=1), Ascending (N=1), 
Sigmoid (N=2), Rectum 
(N=4), Hepatic fixture (N=1) n/a n/a n/a 
Lymph Node 
Involvement 
Positive (N=9), Negative 
(N=5) n/a n/a n/a 
Average Tumor Size 4.2 + 2.9 cm n/a n/a n/a 
Mesenteric Deposits 
Absent (N=7), Present 
(N=8) n/a n/a n/a 
Supplementary Table 2 
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 2 
ABSTRACT: 45 
Objective: Blood vessel epicardial substance (BVES) is a tight junction-associated 46 
protein that regulates epithelial-mesenchymal states and is underexpressed in epithelial 47 
malignancy. However, the functional impact of BVES loss on tumorigenesis is unknown. 48 
Here we define the in vivo role of BVES in colitis-associated cancer (CAC), its cellular 49 
function, and its relevance to inflammatory bowel disease (IBD) patients.  50 
Design: We determined BVES promoter methylation status using an Infinium 51 
HumanMethylation450 array screen of patients with ulcerative colitis with and without 52 
CAC. We also measured BVES mRNA levels in a tissue microarray consisting of normal 53 
colons and CAC samples. Bves
-/- 
and wild-type mice (controls) were administered 54 
azoxymethane (AOM) and dextran sodium sulfate (DSS) to induce tumor formation. 55 
Lastly, we utilized a yeast two-hybrid screen to identify BVES interactors and performed 56 
mechanistic studies in multiple cell lines to define how BVES reduces c-Myc levels.  57 
Results: BVES mRNA was reduced in tumors from patients with CAC via promoter 58 
hypermethylation. Importantly, BVES promoter hypermethylation was concurrently 59 
present in distant non-malignant appearing mucosa. As seen in human patients, Bves was 60 
underexpressed in experimental inflammatory carcinogenesis, and Bves
-/-
 mice had 61 
increased tumor multiplicity and degree of dysplasia after AOM/DSS administration. 62 
Molecular analysis of Bves
-/- 
tumors revealed Wnt activation and increased c-Myc levels. 63 
Mechanistically, we identified a new signaling pathway whereby BVES interacts with 64 
PR61α, a PP2A regulatory subunit, to mediate c-Myc destruction.  65 
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 3 
Conclusions: Loss of BVES promotes inflammatory tumorigenesis through 66 
dysregulation of Wnt signaling and the oncogene c-Myc. BVES promoter methylation 67 
status may serve as a CAC biomarker.  68 
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SUMMARY BOX 70 
What is already known about this subject? 71 
 Patients with ulcerative colitis are at greater risk for developing colon cancer. 72 
 Blood vessel epicardial substance (BVES) is a tight junction protein that regulates 73 
epithelial-to-mesenchymal transition in vitro. 74 
 c-Myc is an oncogene overexpressed in 50% of all malignancies, including colitis-75 
associated cancer (CAC).  76 
 What are the new findings? 77 
 BVES promoter hypermethylation is present in CAC and distant uninvolved mucosa. 78 
 BVES is underexpressed in patients with CAC compared to normal colonic tissue. 79 
 Deletion of Bves promotes colitis-associated tumor multiplicity and dysplasia. 80 
 BVES directs the PR61α-PP2A complex to target c-Myc for proteasomal destruction. 81 
How might it impact on clinical practice in the foreseeable future?  82 
 BVES promoter hypermethylation status is a potential biomarker to identify UC 83 
patients at risk for cancer. 84 
 Our studies demonstrate a new mechanism for regulation of c-Myc, an oncogene that 85 
is dysregulated in numerous malignancies. 86 
 BVES plays a key role in maintaining the integrity of the colonic mucosa and 87 
protecting from inflammatory carcinogenesis, and may represent a therapeutic target 88 
in CAC. 89 
 90 
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 5 
INTRODUCTION 92 
Chronic inflammation promotes the development of colorectal cancer (CRC)
1,2
. 93 
Patients with inflammatory bowel disease (IBD), for example, have an elevated risk of 94 
developing CRC
3
, particularly those who have extensive disease or long disease 95 
duration
4
. Although the pathogenesis of inflammatory carcinogenesis remains unclear, at 96 
least one component of malignant degeneration is thought to be disruption of intestinal 97 
epithelial function as a consequence of chronic inflammation
5,6
. Indeed, pathologic 98 
changes in adherens and tight junction proteins have been described in colitis and colitis-99 
associated cancer (CAC)
6–8
. In addition to providing junctional integrity between cells, 100 
adherens and tight junctional complexes also transduce extracellular signals to direct 101 
intracellular programs (“outside-in” signaling
9
), such as those controlling cellular 102 
proliferation and differentiation. For example, E-cadherin can sequester β-catenin at the 103 
cell membrane, preventing its nuclear localization and transcriptional activity
10
. Given 104 
that dysregulation of junctional proteins commonly occurs in CAC, understanding their 105 
function in normal biology may yield clues to how their dysfunction promotes 106 
carcinogenesis.   107 
Blood vessel epicardial substance (BVES/POPDC1) is a tight junction-associated 108 
protein often silenced in carcinomas secondary to promoter hypermethylation
11–13
. 109 
Restoring BVES expression in CRC cell lines promotes epithelial-like morphology and 110 
decreases proliferation, migration, invasion, xenograft tumor growth, and metastasis, 111 
together indicating broad regulatory capabilities
11
. Conversely, knockdown of BVES in 112 
epithelial-like cells induces a mesenchymal-like phenotype characterized by increased 113 
proliferation, altered morphology, and disorganized cell-cell contacts
11
. Yet how BVES 114 
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 6 
regulates these phenotypes is incompletely understood. Indeed, while several BVES 115 
interacting proteins have been identified
11
, their known functions do not explain fully the 116 
role of BVES in maintaining epithelial phenotypes. Moreover, how BVES contributes to 117 
tumor development has not been tested using genetic approaches.  118 
The transcription factor c-Myc is commonly overexpressed in cancer
14,15
 and 119 
regulates proliferation, differentiation, apoptosis, and epithelial-to-mesenchymal 120 
transition
16
. In mouse models of sporadic CRC, decreased c-Myc levels reduce Apc-121 
driven tumorigenesis
17
. In IBD, c-Myc is overexpressed in both inflamed tissues and 122 
CAC tumors
18
, and network analysis of CAC samples indicated that c-Myc dysregulation 123 
functionally contributes to CAC progression
19
. c-Myc levels are also increased in 124 
experimental models of inflammatory carcinogenesis, such as the azoxymethane 125 
(AOM)/dextran sodium sulfate (DSS) mouse model of CAC
20
. Yet the processes 126 
responsible for c-Myc dysregulation in inflammatory carcinogenesis remain unidentified. 127 
To date, a complex network of proteins—including protein phosphatase 2A (PP2A), 128 
Axin1, and GSK3β—has been identified that regulates c-Myc protein levels by 129 
modifying the phosphorylation status of c-Myc at two residues, threonine 58 (T58) and 130 
serine 62 (S62)
21
. Ubiquitylation of c-Myc is initiated by phosphorylation at T58, leading 131 
to its ultimate degradation. Given the prominent role of c-Myc in driving oncogenic 132 
programs, understanding mechanisms that control PP2A dephosphorylation of c-Myc 133 
may identify new therapeutic targets in inflammatory carcinogenesis.  134 
 Here we report that BVES is an important regulator of inflammatory 135 
carcinogenesis programs and promotes c-Myc degradation through an interaction with the 136 
PR61α-PP2A complex. We observed that BVES is reduced in human CAC samples, and 137 
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 7 
further that the BVES promoter was hypermethylated within the tumors and at distant 138 
unaffected mucosa, suggesting a field effect. Using the AOM/DSS inflammatory 139 
carcinogenesis model, we determined that Bves
-/-
 mice demonstrate greater tumor 140 
incidence and multiplicity as well as a higher degree of dysplasia and intratumoral 141 
proliferation. Furthermore, molecular analysis of Bves
-/-
 tumors revealed increased c-Myc 142 
protein and signaling activity. c-Myc protein was also elevated in intestinal crypts from 143 
Bves
-/- 
mice. In line with in vivo results, knockdown of BVES in vitro increased c-Myc 144 
stability and consequently increased expression of key c-Myc targets ODC and CAD. 145 
Conversely, BVES overexpression reduced c-Myc stability and increased c-Myc 146 
ubiquitylation. Using a yeast two-hybrid (Y2H) screen, we identified PR61α, the PP2A 147 
regulatory subunit critical for c-Myc degradation, as a BVES-interacting protein, and 148 
show that this interaction is required for BVES to modulate cellular c-Myc levels. Thus, 149 
we demonstrate that BVES coordinates PR61α-containing PP2A phosphatase complexes 150 
to restrict c-Myc protein levels and that BVES is a key suppressor of inflammatory 151 
carcinogenesis whose promoter methylation status may define patients with ulcerative 152 
colitis (UC) at risk for colon cancer.   153 
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 8 
MATERIALS AND METHODS 154 
Mice, treatments, and analysis 155 
AOM and DSS were prepared as previously described
22
. Bves
-/-
 mice have been 156 
previously described
23
. Detailed protocols can be found in the Supplementary Materials 157 
and Methods Section.  158 
 159 
BVES promoter methylation analysis 160 
Tissue samples were obtained from colectomy specimens from individuals without UC, 161 
individuals with UC but without dysplasia or cancer, and UC patients with high-grade 162 
dysplasia and/or colon cancer.  Clinical information is described in online 163 
supplementary table 1. Detailed protocols regarding epithelial isolation, methylation 164 
array, and pyrosequencing can be found in the Supplementary Materials and Methods 165 
Section. 166 
 167 
See Supplementary Materials and Methods for detailed methods regarding cell culture 168 
experiments, RNA scope, promoter methylation analyses, and mouse analysis. 169 
 170 
  171 
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 9 
RESULTS 172 
BVES is downregulated and its promoter is hypermethylated in CAC 173 
As BVES is underexpressed via promoter hypermethylation in CRC
11
, we asked 174 
whether the BVES promoter was also hypermethylated in CAC. Therefore, we analyzed 175 
BVES methylation status in an Infinium HumanMethylation450 array screen of IBD 176 
samples. The samples consisted of control patients (Control—No UC), patients with UC 177 
who did not have cancer (UC—no HGD/CAC), and two different types of samples from 178 
patients with UC who had colon cancer: the remote, non-malignant tissue (UC—179 
concurrent HGD/CAC) and tissue with high-grade dysplasia and/or cancer 180 
(HGD/CAC). These analyses demonstrated that the BVES promoter was unmethylated in 181 
the controls–No UC (0.1% + 0.016%), moderately methylated in UC–no HGD/CAC 182 
(16% + 4.7%), and hypermethylated in the HGD/CAC among patients with colitis-183 
associated carcinoma (HGD/CAC, 53% + 2.6%) (figure 1A). Furthermore, remote non-184 
neoplastic, mucosal samples (UC-Concurrent HGD/CAC) from the same patients who 185 
had CAC (HGD/CAC) were hypermethylated (50% + 2.6%) to a similar degree as that 186 
observed in cancerous tissue. Interestingly, these results suggest that BVES promoter 187 
methylation may represent a field effect in CAC and that BVES promoter methylation 188 
status may identify UC patients with concurrent malignancy. To confirm the results 189 
derived from the HM450 methylation array studies, we pyrosequenced the BVES 190 
promoter in the same samples and again demonstrated low levels of methylation in the 191 
UC—no HGD/CAC cases, and higher methylation in both the UC—concurrent 192 
HGD/CAC and HGD/CAC cases (figure 1B).  193 
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 10
It is possible that BVES promoter methylation, while increased, may not be 194 
sufficient to silence its expression. To determine whether BVES promoter methylation 195 
indeed reduced its transcription, we tested whether BVES mRNA was downregulated in 196 
CAC using high resolution in situ hybridization (RNAScope
24
) in a tissue microarray 197 
consisting of normal, UC, and CAC samples. BVES mRNA levels were low, but 198 
consistently present in normal colonic epithelial cells (figure 1C). In UC and CAC 199 
samples, however, BVES message was rarely detected and quantification of epithelial 200 
staining indicated a 5-fold decrease (p<0.001). Taken together, BVES RNA expression is 201 
downregulated in both UC and CAC, most likely due to promoter hypermethylation. 202 
Furthermore, as the BVES promoter is hypermethylated in both tumor and non-malignant 203 
mucosa in patients with CAC, BVES promoter methylation may serve as a biomarker 204 
associated with dysplasia or neoplasia in patients with IBD. 205 
Bves loss promotes CAC development  206 
While BVES underexpression was consistently observed in human CAC, these 207 
studies do not establish whether BVES loss actively promotes tumorigenesis. Therefore, 208 
we used mouse genetic approaches combined with the AOM/DSS model (figure 2A) to 209 
determine if BVES loss contributed to inflammatory tumorigenesis. While Bves was 210 
expressed at baseline in the murine colon at both the RNA and protein levels (see online 211 
supplementary figure 1), transcriptome profiling of AOM/DSS-induced tumors in WT 212 
mice showed a 5-fold decrease in Bves transcripts (figure 2B), mirroring the results 213 
observed in human CAC. As expected, we also observed changes in other tight junction 214 
constituents, supporting previous reports of tight junctional dysregulation in colitis and 215 
CAC
25
. We confirmed that Bves message was decreased in AOM/DSS tumor tissue by 216 
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qPCR in an independent sample set (figure 2B). Interestingly, Bves message also 217 
decreased in AOM/DSS treated non-malignant tissue compared to normal colons (figure 218 
2B), again suggesting a field effect in inflammatory carcinogenesis. As a result, we 219 
hypothesized that complete loss of Bves might promote inflammatory carcinogenesis.  220 
To test the effect of Bves loss in CAC, we compared WT and Bves
-/- 
mice 221 
subjected to the same inflammatory carcinogenesis protocol. We first observed that Bves
-
222 
/-
 mice lost a greater fraction of body weight compared to WT mice, most notably during 223 
cycle 3 (figure 2C), suggesting increased sensitivity to AOM/DSS treatment. Indeed, 224 
endoscopy one-week prior to sacrifice demonstrated increased tumor multiplicity in Bves
-
225 
/-
 mice (figure 2D) and this was confirmed at necropsy where we observed 100% tumor 226 
penetrance in Bves
-/-
 mice compared to 60% in WT mice (figure 2E). Bves
-/-
 mice also 227 
demonstrated increased tumor multiplicity (6.5 ± 0.6 tumors per Bves-/- mouse vs. 2.2± 228 
0.5 tumors per WT mouse, p<0.001), and tumor size (figure 2E). Furthermore, Bves
-/- 
229 
tumors exhibit more advanced dysplasia compared to WT tumors (figure 2F). Control 230 
mice treated with three cycles of DSS-only or a single AOM injection did not develop 231 
tumors during this time-frame (data not shown). Taken together, these results suggest that 232 
BVES underexpression in CAC functionally contributes to inflammatory carcinogenesis. 233 
Increased proliferation and enhanced Wnt activation in Bves
-/- 
tumors 234 
 235 
To identify BVES-directed mechanisms responsible for modifying tumorigenesis, 236 
we examined proliferation and apoptosis in the tumors of AOM/DSS treated Bves
-/- 
mice. 237 
Proliferation, as measured by phospho-histone H3 staining, was increased in Bves
-/-
 238 
tumors (figure 3A). Conversely, staining for cleaved caspase-3 indicated no difference in 239 
intratumoral apoptosis between Bves
-/- 
and WT mice (see online supplementary figure 240 
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2). As Wnt activation can drive proliferation, we postulated that Wnt signaling might be 241 
perturbed in Bves
-/-
 tumors. β-catenin dysregulation is a key indicator of hyperactive Wnt 242 
signaling
26
, and β-catenin is also a mutational target in DMH/DSS inflammatory 243 
carcinogenesis, resulting in increased levels and altered subcellular distribution
27
. 244 
Therefore, we analyzed β-catenin by immunohistochemistry and observed excessive 245 
cytoplasmic and nuclear β-catenin localization in Bves
-/-
 tumors compared to WT tumors 246 
(figure 3B). While these results suggested hyperactive Wnt signaling in Bves
-/- 
tumors, 247 
we confirmed this by RNA-seq analysis, which indicated upregulation of established Wnt 248 
targets, such as Mmp7, Wisp2, and Rspo4 (figure 3C), in Bves
-/- 
tumors. Ingenuity 249 
Pathway Analysis (IPA)
28
 of the RNA-seq data set also indicated hyperactive Wnt 250 
networks, such as β-catenin and Tcf. Finally, immunoblotting demonstrated greater 251 
expression of cyclin D1 and c-jun, two well-characterized Wnt target genes
29,30
, in Bves
-/- 
252 
tumors (figure 3D). While previous experiments demonstrated that BVES could regulate 253 
Wnt signaling using in vitro, cell-based assays
11
, these findings provide the first in vivo 254 
and genetic evidence supporting the hypothesis that BVES regulates Wnt activity. 255 
BVES regulates c-Myc degradation  256 
 As c-Myc is a bona-fide Wnt transcriptional target
17
, has been identified as a 257 
potential biomarker in patients with IBD at risk for CAC
19
, and is overexpressed in 258 
AOM/DSS tumors
20
, we postulated that c-Myc was dysregulated in Bves
-/- 
tumors. 259 
Indeed, IPA analysis of intratumoral transcriptomes identified causal dysregulation
28
 of 260 
c-Myc networks (see online supplementary figure 3A). While analysis of RNA-seq 261 
datasets showed only a modest increase in c-Myc transcripts in Bves
-/- 
tumors compared 262 
to WT tumors (see online supplementary figure 3B), immunohistochemical staining for 263 
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c-Myc demonstrated an increase in both total c-Myc protein (figure 4A) and 264 
transcriptionally active, phosphorylated serine 62 c-Myc species in Bves
-/-
 tumors (see 265 
online supplementary figure 4). Interestingly, immunoblotting in tumor-adjacent 266 
mucosa also showed higher c-Myc levels in Bves
-/-
 colons, which suggested c-Myc was 267 
increased prior to tumor formation and that BVES might regulate c-Myc levels in the gut 268 
at baseline (figure 4B). To test this, we isolated crypts from untreated Bves
-/-
 and WT 269 
mice and observed greater c-Myc protein in Bves
-/-
 samples (figure 4C). Consistent with 270 
elevated c-Myc, qPCR for Ornithine decarboxylase (Odc), a c-Myc transcriptional target, 271 
indicated a 4-fold increase in Bves
-/- 
colons (see online supplementary figure 5). We 272 
also observed increased mRNA of c-Myc targets Odc and E2f transcription factor 2 273 
(E2f2) (figure 4D) in “mini-gut” 3D cultures, demonstrating that BVES regulation of c-274 
Myc activity was epithelial cell-autonomous. 275 
 As we observed increased c-Myc protein in Bves
-/- 
tumors, we postulated that 276 
BVES could regulate c-Myc protein stability. Three cell lines—HEK 293T (non-277 
malignant cell line), Caco2 (CRC cell line that can form a polarized epithelium), and 278 
HCE (Human Corneal Epithelial)—which all express BVES (supplementary figure 6)
11
 279 
were used for BVES knockdown experiments. In all three cell lines, BVES RNAi 280 
increased c-Myc protein levels (figure 5A and supplementary figure 7). In addition to 281 
increasing total c-Myc protein, we also observed that BVES knockdown reduced T58 282 
phosphorylation, a key post-translational modification which signals for c-Myc 283 
degradation by the ubiquitin-proteasome system (figure 5A). This increase in c-Myc was 284 
functionally relevant as transcript levels of c-Myc targets ODC and Carbamoyl-285 
Phosphate Synthetase 2 Aspartate Transcarbamylase and Dihydroorotase (CAD) were 286 
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increased with BVES knockdown (figure 5B). Furthermore, knockdown of BVES 287 
doubled c-Myc half-life compared to non-targeting control samples (figure 5C). 288 
Conversely, overexpressing BVES reduced c-Myc protein levels, increased T58 c-Myc 289 
species (figure 5D), dampened c-Myc transcriptional activation of the c-Myc responsive 290 
E2F2 reporter (see online supplementary figure 8), and decreased c-Myc protein half-291 
life (figure 5E, lower panel). We then tested whether BVES could regulate c-Myc 292 
ubiquitylation, a central post-translational event targeting its destruction. Indeed, by 293 
overexpressing BVES we observed increased c-Myc polyubiquitylation (figure 5F). 294 
Moreover, inhibiting the proteasome using MG132 blocked BVES-induced reduction of 295 
c-Myc (figure 5F). Hence, our results suggest that BVES promotes the post-translational 296 
degradation of c-Myc. 297 
BVES interacts with PR61α, PP2Ac, and c-Myc 298 
To identify a molecular mechanism by which BVES orchestrates c-Myc 299 
degradation, we conducted a Y2H screen to define the BVES interactome. 300 
Characterization of this interactome using the PANTHER (Protein ANalysis THrough 301 
Evolutionary Relationships) Classification System
31
 identified a number of biologic 302 
processes influenced by BVES (figure 6A). Interestingly, the screen identified that 303 
BVES interacted with four of the five members of the B’ family of PP2A regulatory 304 
subunits (PPP2R5A, PPP2R5B, PPP2R5D, and PPP2R5E). PPP2R5A, also known as 305 
PR61α, is a key regulator of PP2A mediated c-Myc dephosphorylation. PR61α directs 306 
the heterotrimeric PP2A complex, consisting of a regulatory, catalytic, and structural 307 
subunit, to associate with doubly phosphorylated (T58/S62) c-Myc and dephosphorylate 308 
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S62, resulting in increased levels of monophosphorylated T58 c-Myc species, which 309 
signals c-Myc to be degraded by the proteaosome
32
.  310 
The BVES:PR61α interaction was then confirmed by directed Y2H (figure 6A) 311 
and by exogenous and endogenous co-immunoprecipitation in HEK 293T cells (figure 312 
6B and C). If BVES were interacting with PR61α to promote c-Myc degradation, we 313 
hypothesized that BVES would complex with both the PP2A catalytic subunit (PP2Ac) 314 
and c-Myc, which we then demonstrated by co-immunoprecipitation (figure 6D and E 315 
and see online supplementary figure 9). We further used the proximity ligation assay 316 
(PLA) and confirmed interaction of both exogenous and endogenous BVES with 317 
endogenous PR61α and c-Myc (figure 6F). Overall, these data indicate that BVES 318 
complexes with c-Myc, PR61α, and the PP2A catalytic subunit. 319 
BVES is essential for PR61α-mediated c-Myc degradation 320 
PP2A dephosphorylation of S62 requires c-Myc to be phosphorylated at residue 321 
T58
33
. If BVES reduces c-Myc through PP2A, we reasoned c-Myc
T58A
, a c-Myc
 
mutant 322 
resistant to T58 phosphorylation, would escape BVES-induced degradation.  Indeed, 323 
BVES expression consistently reduced c-Myc
WT
 but had no effect on c-Myc
T58A
 (figure 324 
7A). We next hypothesized that knockdown of BVES would ablate PR61α-PP2A 325 
induced c-Myc degradation. Overexpression of PR61α reduced c-Myc protein subtly but 326 
consistently as previously reported
32
 (figure 7B; compare lane 1 and 3). Knocking down 327 
BVES, however, rescued PR61α-induced degradation (figure 7B; compare lanes 3 and 328 
4). We then tested whether BVES could enhance PR61α-mediated c-Myc degradation, 329 
and indeed, overexpression of BVES and PR61α substantially reduced c-Myc protein 330 
compared to PR61α or BVES alone (figure 7C; compare lane 4 to 2 or 3). 331 
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We then sought to determine whether BVES requires PR61α to degrade c-Myc. 332 
For these experiments we first mapped the BVES:PR61α interaction domain by serial 333 
deletions to the carboxy-terminus of BVES. Deleting the carboxy-terminal 30 residues, 334 
but not the last 15 residues, disrupted the BVES:PR61α interaction as demonstrated by 335 
Y2H and by co-IP, thus mapping the interaction domain to residues 330-345 (figure 7D). 336 
Importantly, this uncoupling mutant (BVES-330) demonstrated reduced affinity for c-337 
Myc (figure 7E) and was unable to reduce c-Myc levels (figure 7F), indicating BVES 338 
indeed requires interaction with PR61α to regulate c-Myc. Overall, our results 339 
demonstrate that BVES, through PR61α, promotes c-Myc dephosphorylation, 340 
destabilization, and destruction, and thus provides mechanistic insight into one manner 341 
by which BVES may contribute to inflammatory carcinogenesis.   342 
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DISCUSSION 343 
We, and others, have shown that BVES is underexpressed in gastrointestinal 344 
cancers and that restoration of BVES in cancer cell lines induces epithelial features. Here 345 
we provide the first genetic evidence that BVES modifies cancer phenotypes, as we 346 
demonstrate that mice lacking Bves have increased tumor multiplicity and dysplasia after 347 
establishment of inflammatory carcinogenesis. Further, we show Bves
-/-
 tumors have 348 
increased c-Myc protein resulting in activation of c-Myc regulated networks. Moreover, 349 
we identify that BVES interacts with PR61α, a key regulatory subunit of the PP2A 350 
phosphatase complex, and promotes PP2A-mediated c-Myc dephosphorylation leading to 351 
c-Myc degradation. Uncoupling the BVES:PR61α interaction blocks BVES-dependent 352 
reduction of cellular c-Myc levels. To our knowledge, this is the first junctional-353 
associated protein identified that regulates post-translational c-Myc status. The potential 354 
clinical relevance is demonstrated as we observed that BVES is downregulated in CAC 355 
likely secondary to promoter methylation. However, perhaps more importantly, we 356 
establish that the BVES promoter is also aberrantly methylated in distant, normal 357 
appearing tissues in patients with CAC/HGD—suggesting a field effect. Thus, our 358 
findings not only reveal that deletion of BVES promotes CAC, but also that BVES 359 
promoter methylation status may be a clinically important surrogate marker of colitis-360 
associated dysplasia or CAC in IBD patients.  361 
Chronic colitis has been shown to accelerate genome-wide methylatio  changes
34
; 362 
it has been hypothesized that this greater rate of methylation contributes to the increased 363 
cancer risk in patients with colitis by silencing tumor suppressors. Understanding how 364 
methylation broadly affects inflammatory tumorigenesis is important to design therapies 365 
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and screening strategies for IBD patients. Our report specifically identifies that the BVES 366 
promoter is hypermethylated in UC patients who have CAC. Interestingly, BVES 367 
promoter hypermethylation is observed not only in the cancerous tissue, but also in the 368 
non-malignant mucosa in these patients. Currently, the standard method of cancer 369 
screening in IBD patients, who are at up to a 10-fold elevated risk of developing CAC
1
, is 370 
surveillance colonoscopy performed with the hope that cancer will be detected at an 371 
early, treatable stage. Yet the detection of neoplasia in the colon can be challenging in 372 
individuals with IBD, as the lesions are frequently flat and difficult to detect in a 373 
background of acute and chronic inflammatory changes. Our data suggest that aberrant 374 
BVES promoter methylation may be a useful biomarker for the presence of CAC, or even 375 
dysplasia, and that measuring BVES promoter methylation status could serve as a 376 
clinically useful tool to identify patients at risk for colon dysplasia or cancer. 377 
While the molecular pathogenesis of CAC remains incompletely understood, 378 
recent work has shown the importance of NF-κB signaling
35
, the intestinal microbiota
36
, 379 
the tumor microenvironment
37
, and the innate immune system
38
 in regulating 380 
inflammatory tumorigenesis. A growing body of evidence also supports the important 381 
role of epithelial junctional constituents in inflammation and CRC. For example, mice 382 
expressing a dominant negative N-cadherin display disrupted adherens junctions and 383 
develop severe inflammation and colitis-associated dysplasia
39
. Likewise, knocking out 384 
Junctional adhesion molecule (Jam-A) results in a dramatic increase in susceptibility to 385 
DSS-induced colitis
8
. Here we show that deletion of Bves, a tight junction-associated 386 
protein, augments inflammatory carcinogenesis. Indeed, loss of BVES appears to 387 
increase tumor initiation and progression. We postulate that this is likely due to dual 388 
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regulation of Wnt signaling and c-Myc protein degradation. Our results further strengthen 389 
the concept that junctional constituents are important regulators of colitis-induced tumor 390 
initiation and progression.  391 
In the last decade, BVES has been shown to regulate a variety of cellular 392 
processes. For example, a Y2H screen of a mouse heart library identified an interaction 393 
between BVES and GEFT, a guanine nucleotide exchange factor
40
. Indeed, it was shown 394 
that expression of BVES modulated cell shape and locomotion, thus linking BVES to 395 
Rho-family GTPase signaling
40
. BVES has also been shown, via an interaction with ZO-396 
1, to regulate GEF-H1-mediated RhoA activity
11
. More recently, it was reported that 397 
BVES plays a regulatory role in cardiac pacemaking through binding of cAMP and 398 
interacting with potassium channel TREK-1
41
. Further, BVES interacts with CAV3, a 399 
caveolin expressed in the muscle tissue, and cardiac myocytes in Bves
-/-
 mice have altered 400 
calveolar number and size
42
. Thus, BVES, through scaffolding with protein complexes, 401 
regulates a wide variety of basic, yet essential, cellular processes.  402 
Our results now expand the known regulatory roles of BVES to include 403 
maintaining appropriate c-Myc protein levels. We show that BVES, through its 404 
interaction with the PR61α-containing PP2A phosphatase complex, can promote c-Myc 405 
degradation and that silencing BVES prevents PR61α-induced degradation of c-Myc. 406 
Moreover, mutating BVES so that it is unable to associate with PR61α renders BVES 407 
unable to initiate c-Myc destruction. The post-translational regulation of c-Myc requires 408 
coordination of numerous proteins to modify its phosphorylation and ubiquitylation 409 
status
21
. Precisely how BVES coordinates the PR61α-PP2A complex remains to be 410 
understood, but given that analysis of BVES structure shows no apparent enzymatic 411 
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motifs in BVES, it is likely that BVES acts as a scaffold allowing for complex formation, 412 
similar to AXIN1
21
. Interestingly, in addition to the membranous staining of the 413 
BVES:PR61α complex, there also appears to be peri-nuclear and cytoplasmic 414 
localization (figure 6F), which is consistent with previous reports describing the dynamic 415 
subcellular localization of BVES and its family members
43
. The PP2A family has been 416 
associated with tight junctional complexes regulating cellular permeability, but their 417 
exact role remains controversial
44
. BVES may bridge PP2A complexes to tight junctions 418 
and our report adds a new molecular mechanism for “outside-in” signaling in the 419 
epithelium.  420 
Because c-Myc regulates thousands of genes, even subtle changes in c-Myc 421 
expression can have profound effects on cellular transcriptomes that promote 422 
tumorigenesis
45
. Indeed, strict regulation of c-Myc is an important component of 423 
homeostasis, and this is particularly true in the intestine. Acute expression of c-Myc, for 424 
example, dramatically expands the intestinal crypts and results in loss of differentiated 425 
cells
46
. Moreover, it has been shown that c-Myc is essential for Apc-mediated intestinal 426 
tumorigenesis
17
. Thus, BVES may serve as an important suppressor of inflammatory 427 
tumorigenesis via attenuating excessive c-Myc levels. More broadly, BVES could act as a 428 
regulator of c-Myc in a variety of tissues, as BVES is expressed in most epithelial tissues, 429 
such as lung, stomach, and breast, and its downregulation or promoter hypermethylation 430 
has been documented in diverse epithelium
11–13
.  431 
Taking our data together, one can envision a model in which chronic 432 
inflammation leads to BVES promoter hypermethylation, resulting in suppression of 433 
BVES transcription and reduced cellular protein levels. Loss of BVES impairs PR61α 434 
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directed PP2A dephosphorylation of c-Myc, thus favoring increased cellular pools of c-435 
Myc, a potent oncogene, likely, in cooperation with other oncogenic events,  contributing 436 
to tumor progression (figure 8). 437 
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Legends 569 
Figure 1 A field effect of BVES promoter hypermethylation in colitis-associated cancer. 570 
(A) Average BVES promoter methylation status in the indicated sample from the Infinium 571 
HumanMethylation 450 Array. Methylation was measured in four sample types: colon 572 
epithelia from patients who did not have UC (Control—No UC); colon epithelia from UC 573 
patients who did not have dysplasia or carcinoma (UC—no HGD/CAC); non-malignant 574 
colon epithelia from UC patients (UC—concurrent HGD/CAC) and malignant colon 575 
epithelia (HGD/CAC) from UC patients who had dysplasia/carcinoma. Control—No UC, 576 
n=17; UC—no HGD/CAC, n=11; UC—concurrent HGD/CAC, n=10; HGD/CAC, n=10. 577 
**p<0.01. 578 
(B) Pyrosequencing at four sequential CpG dinucleotides in the BVES promoter. Each 579 
shape represents a separate individual, with mean methylation values depicted with black 580 
bars. ***p<0.001. 581 
(C) Representative images of high-resolution in situ (RNAscope™) analysis of BVES 582 
message in normal colons (n=11), UC (n=13), and CAC (n=19). Right: Quantification of 583 
BVES expressing epithelial cells per tissue microarray core. Size standard=50 microns. 584 
***p<0.001 585 
 586 
Figure 2 BVES modifies inflammatory carcinogenesis.  587 
(A) Schematic of AOM/DSS protocol and timeline. Mice were injected with 7.5 mg/kg of 588 
AOM and treated with 2.5% DSS at the indicated time. 589 
(B) Left: Heat map of RNA-seq data derived from WT colons (n=3) and WT AOM/DSS 590 
tumors (n=3). Red indicates genes increased and green indicates genes decreased in 591 
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tumors compared to normal colon. Right: qPCR of Bves message levels in normal colons 592 
(Normal, n=5), non-malignant AOM/DSS treated colon (NM, n=5) and AOM/DSS tumor 593 
(Tumor, n=6). Tissue harvested from WT mice after AOM/DSS treatment. ***p<0.001. 594 
(C) Weights of Bves
-/- 
and WT mice during AOM/DSS treatment. Weights are presented 595 
as fraction of initial weight. Bves
-/- 
(male: n=8, female: n=7) and WT (male: n=5, female: 596 
n=10). *p<0.05, ***p<0.01, ***p<0.001. 597 
(D) Representative colonoscopy images of WT and Bves
-/-
 colons after the second cycle 598 
of DSS treatment. Right: Quantification of tumor multiplicity by endoscopy assessment.  599 
(E) Tumor incidence, multiplicity, and size distribution at necropsy in WT and Bves
-/-
 600 
mice. Blue = female mice, black = male mice.*p<0.05, ***p<0.001. 601 
(F) Left: Representative H&E stained sections demonstrating the histologic features of 602 
WT and Bves
-/- 
tumors. Size standard=100 microns. Right: Blinded histological scoring of 603 
degree of dysplasia of tumors from WT and Bves
-/-
 mice. Graph represents percentage of 604 
mice with intratumoral low or high-grade dysplasia.  605 
 606 
Figure 3 Dysregulated Wnt signaling in Bves
-/- 
tumors. 607 
(A) Left: Representative images of phospho-histone H3 (pH3) immunohistochemistry in 608 
WT and Bves
-/-
 tumors. Size standard=50 microns. Right: Quantification of pH3 positive 609 
cells per tumor high power field (HPF). Data is presented as the mean number of positive 610 
cells per tumor HPF per mouse. At least five HPF per mouse were scored. Student’s t 611 
test, *p<0.05. 612 
(B) Left: H&E stained sections, size standard=50 microns. Middle: Representative 613 
images of β-catenin immunohistochemistry, low magnification, size standard=50 614 
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microns. Right: β-catenin immunohistochemistry, high magnification, size standard=20 615 
microns. Far right: Quantification of intratumoral β-catenin immunohistochemistry. An 616 
index was employed to quantify extent of nuclear and cytoplasmic β-catenin staining. 617 
This index is generated by multiplying the staining intensity (on a scale of 100-500) by 618 
percentage of the cells demonstrating nuclear staining. For example, a score of 500 619 
indicates a field that demonstrated very intense nuclear β-catenin stain while a score of 620 
100 indicates a fi ld that has weak nuclear β-catenin staining. Data is presented as the 621 
mean score per tumor HPF per mouse. At least five HPF per mouse were scored. 622 
(C) Wnt target genes upregulated in Bves
-/- 
tumors identified in RNA-seq dataset (WT, 623 
n=3; Bves
-/-
,
 
n=3).  624 
(D) Immunoblot of Cyclin D1 and c-jun in Bves
-/-
 and WT tumors. β-actin was used as a 625 
loading control.  626 
 627 
Figure 4 c-Myc signaling is dysregulated in Bves
-/-
 mice in inflammatory carcinogenesis. 628 
(A) Left: Representative images of immunohistochemistry for intratumoral c-Myc. Right: 629 
quantification of c-Myc positive cells per tumor high power field (HPF). HPFs were 630 
scored according to an index from 1-4 (a score of 1 denotes less than 25% of positive 631 
cells per HPF; a score of 2 denotes 25-50%; a score of 3 denotes 50-75%; a score of 4 632 
denotes 80-100%). Data is presented as the mean score per tumor HPF per mouse. At 633 
least five HPF per mouse were scored. Student’s t test, *p<0.05. Size standard=50 634 
microns 635 
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(B) Immunoblot of c-Myc in WT and Bves
-/-
 normal adjacent colons. Blots were imaged 636 
using the LiCor Odyssey system and quantified using Image Studio analysis. Student’s t 637 
test, p<0.05. 638 
(C) Immunoblot of c-Myc in WT (n=3) and Bves
-/- 
(n=3) intestinal crypts.  639 
(D) qPCR for Odc and E2f2 in enteroid cultures Student’s t test, *p<0.05.  640 
In all western blots, β-actin served as loading control. 641 
 642 
Figure 5 BVES regulates c-Myc stability and activity.  643 
(A) c-Myc and T58 phospho-c-Myc protein levels after BVES knockdown in HEK 293T 644 
(left) or Caco2 (right) cells after 48 hr serum starvation.  645 
(B) qRT-PCR assay for c-Myc targets ODC and CAD following BVES knockdown in the 646 
indicated cell lines. Data are presented as mean ±SEM and in triplicates. *p<0.05, 647 
**p<0.01. 648 
(C) Cycloheximide treatment (100 µg/ml) of HEK 293T cells with and without Bves 649 
knockdown followed by immunoblotting for c-Myc.  650 
(D) c-Myc and T58 phospho-c-Myc protein levels after overexpression of V5:BVES in 651 
HEK 293T cells.  652 
(E) HEK 293T cells co-transfected with HA:c-Myc and V5:BVES were then treated with 653 
cycloheximide (100 µg/ml) followed by immunoblotting for the indicated protein.  654 
(F) Left: His:Ubiquitin and HA:c-Myc were co-transfected into HEK 293T cells along 655 
with V5:BVES. Cells were treated with proteasome inhibitor MG132 (20 µm) for 4 hours 656 
before His:Ubiquitin complexes were immunoprecipitated and resolved by SDS-PAGE. 657 
Ubiquitylated HA:c-Myc complexes were visualized by immunoblotting (Ub-c-Myc). 658 
Total ubiquitylated protein (Total ub) was examined as a control. Right: HEK 293T cells 659 
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co-transfected with HA:c-Myc and V5:BVES were treated with proteasome inhibitor 660 
MG132 (20 µm) for 4 hours. Whole cell lysates were analyzed for HA:c-Myc expression.  661 
In all immunoblots, β-actin was used as a loading control.  All experiments were 662 
replicated three times. 663 
 664 
Figure 6 BVES interacts with PR61α, PP2A, and c-Myc. 665 
 666 
(A) PANTHER Biologic Process Analysis of BVES interactome. Inset: Directed yeast 667 
two-hybrid of BVES and PR61α.  668 
(B) Co-immunoprecipitation of exogenous and (C) endogenous PR61α:BVES complexes 669 
in HEK 293T cells.  670 
(D) Co-immunoprecipitation of V5:BVES and HA:PP2Ac or (E) HA:c-Myc.  671 
(F) Left: Proximity ligation assay in HEK 293T cells transfected with V5:BVES. Left: 672 
control, middle: α-PR61α, right: α-c-Myc. Right: Proximity ligation assay in HEK 293T 673 
cells for endogenous protein interactions. Left: control, middle: α-PR61α, right: α-c-674 
Myc. Anti-HA was used as a control in both exogenous and endogenous localization. 675 
Scale bar denotes 10 µm. Red staining is positive signal from the PLA interaction, and 676 
blue staining is DAPI. In all immunoblots blots, β-actin was used to ensure loading 677 
consistency. All experiments were repeated at least two times. 678 
 679 
Figure 7 The BVES:PR61α interaction is required to promote c-Myc degradation.  680 
(A) WT HA:c-Myc or phospho-mutant HA:T58A c-Myc levels after either empty vector 681 
(negative control) or V5:BVES transfection in HEK 293T cells. 682 
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(B) Immunoblotting for HA:c-Myc levels following PR61α overexpression in the setting 683 
of BVES knockdown or (C) when both PR61α and BVES are present HEK 293T cells. 684 
(D) Top: Mapping the PR61α BVES binding interface via directed yeast two-hybrid (Full 685 
length BVES, residues 1-345, 1-330, 1-302, negative control (Neg Ctrl), and positive 686 
control (Pos Ctrl)). Below: Co-immunoprecipitation of the indicated BVES mutants and 687 
PR61α in HEK 293T cells.. 688 
(E) Co-immunoprecipitation of the indicated BVES mutants and HA:c-Myc in HEK 689 
293T cells. 690 
(F) HA:c-Myc protein levels after transfection of the indicated BVES construct in HEK 691 
293T cells. 692 
In all immunoblots, β-actin was used as a loading control.  All experiments were repeated 693 
at least two times. 694 
 695 
Figure 8 Working model of the role of BVES in regulating c-Myc degradation and 696 
colitis-associated cancer development. 697 
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